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Pharmacovigilance is the science and activities related to the detection, assessment, understanding 
and prevention of adverse effects or any other drug-related problems [1]. The etymological origin 
of ‘pharmacovigilance’ is a mix between the greek word pharmakon (drug) and the latin word 
vigilare (to guard). While medicines are tested in clinical trials before a marketing authorisation is 
granted, trials are necessarily limited in time and in the number and type of patients enrolled [1-3]. 
As a consequence, the possibilities to detect adverse drug reactions (ADRs) prior to marketing are 
limited. In particular, ADRs which are rare, with a long latency or those that occur only in specific 
patient groups or in specific contexts of administration are hard to detect. In addition, once on the 
market, medicines can be used both according to and outside the approved indications (off-label), 
by patients with multiple comorbidities and simultaneously treated with other medications. The 
‘real world’ usage of drugs is more complex, unpredictable and dynamic than the experimental 
situation, and some ADRs cannot be observed in the experimental setting and will only be visible 
after approval. This leads to an uncertainty at approval stage that needs to be dealt with. 
The uncertainty with regards to the safety profile of a drug cannot be completely avoided. However, 
there are ways to minimize it and this can be done through continuous monitoring along the entire 
product lifecycle. One of the pharmacovigilance processes in place to achieve this continuous 
monitoring is signal management. The signal management process is a ‘set of activities performed 
to determine whether, based on an examination of individual case safety reports, aggregated 
data from active surveillance systems or studies, literature information or other data sources, there 
are new risks associated with an active substance or a medicinal product or whether risks have 
changed’ [4]. In this thesis we focus on the European signal management process, referencing signal 
management in other parts of the world as needed, for context. 
SIGNAL MANAGEMENT IN EUROPE 
The European pharmacovigilance legislation adopted in 2010 [5] and operational since 2012 
describes the signal management process. The legislation is supported by the ‘Guideline on good 
pharmacovigilance practices Module IX on Signal management’ [6], which offers guidance on each 
step from signal management process and describes its application in the European Union (EU) 
regulatory network, including each stakeholder role. 
In Europe, the stakeholders involved in the signal management process include patients, healthcare 
professionals, marketing authorisation holders (MAHs), national competent authorities, the European 
Medicines Agency (EMA) and scientific committees such as Pharmacovigilance Risk Assessment 
Committee (PRAC). The PRAC is a scientific committee of EMA that includes members from each 
Member State, independent EC appointed experts, a patient representative and a healthcare 
professionals representative. The role of PRAC in signal management includes prioritisation of 
confirmed signals for further discussion, assessment and recommendations for actions [6]. In 
addition, PRAC is involved in regular revision of signal detection methodologies. 
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Signal management is often described as a sequential process (as shown in Figure 1) [7,8] with the 
following activities: detection, validation, confirmation, analysis and prioritisation, assessment and 
recommendation for action [9]. 
Detection Validation Confirmation AnalysisPrioritization Assessment
Recommendation
for action
EMA, MS EMA, MS PRAC
MAHs
Figure 1: Signal management process and stakeholders’ responsibilities as described in the legislation1
EMA=European Medicines Agency; PRAC=Pharmacovigilance Risk Assessment Committee; MAH=marketing 
Authorisation Holders 
The first step, signal detection, is the process of monitoring safety data for information that suggests 
‘a new potentially causal association, or a new aspect of a known association between an intervention 
and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood 
to justify verificatory action’ [8]. Spontaneous reporting systems are an important focus for signal 
detection. In addition to spontaneous reports, a signal can arise from a wide variety of sources, 
such as aggregated data from active surveillance systems, studies, scientific literature or other data 
sources. In Europe, EudraVigilance database maintained by the EMA [11] is the largest database 
of spontaneous reports and an important source of signals. National competent authorities have 
systems in place to perform signal detection in their national databases as well as in EudraVigilance. 
This monitoring is required by the law. In parallel, marketing authorisation holders are screening their 
databases and from November 2017 onwards they will also monitor EudraVigilance through public 
access. The MAHs have the legal obligation to continuously monitor their products [6] and to report 
any signal found to the competent authorities. Only signals that require urgent attention will be 
reported via a standalone notification, namely an ’emerging safety issue’ [6]. If is not urgent, the signal 
can be reported within the regular periodic safety reports, if the time between signal validation and 
report submission is less than 6 months. Alternatively, the signal can be communicated via update 
of product information or risk management plans, together with the proposed regulatory action. 
The second step of the signal management process is signal validation. In this step, the detected 
signal is evaluated to verify whether there is sufficient evidence to justify further analysis [9]. 
At the end of the validation phase, it has to be decided if the association is at least a reasonable 
possibility and if the signal represents a new safety issue or a new aspect of a known safety issue. 
Various sources of information can be used during the validation phase. Each source has different 
relevance and weight depending on the signal at hand. The most commonly used data sources are: 
spontaneous reports, product information, scientific literature, drug utilisation data and regulatory 
documents such as risk management plans and periodic safety update reports. The third step, 
signal confirmation is a procedural step that identifies those signals that will be discussed at the 
1 Adapted from SCOPE Work Package 5 Signal Management-Best Practice Guide
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next PRAC meeting [6,7]. The fourth step, prioritisation, ranks the signals’ based on their impact 
on patients health, potential public health impact and strength of evidence. High priority means 
urgent attention and management without delay [6]. Sometimes signals with potential high media 
attention are prioritised in order to communicate the results of the assessment as early as possible. 
The fifth step, signal assessment is the assessment of all scientific evidence available related to 
the signal [9]. The aim is to identify the next step: regulatory action, additional data collection or 
signal refutation [12]. As for validation, a wide range of data sources can be used and their relevance 
depends on the signal studied. The most commonly used data sources are: spontaneous reports, 
scientific literature, the application dossier, expert consultation and information provided by 
MAHs [12]. Additionally, pharmacoepidemiological studies can be performed in order to evaluate a 
signal. The studies can be requested to the MAHs or performed by the regulators themselves. 
Despite of the clear signal management process, there are still questions that require further scientific 
investigation. This thesis aims to answer some of these questions and focuses on three areas of 
potential improvement: data sources, methods of detection, and signal prioritisation process. Since 
data sources and detection methods are interdependent, they will be discussed together. 
DATA SOURCES AND METHODS OF DETECTION 
Spontaneous reporting systems 
The first important area for improvement is represented by the data sources for signal detection. 
The most important source for signal detection is spontaneous reporting systems, established 
since the 1960s [8]. Spontaneous reporting systems are passive public health surveillance systems, 
based on reporting of potential adverse events by healthcare professionals and patients. The core 
data elements collected within spontaneous reporting systems are established by international 
agreements [12] and include: an identifiable patient, an ADR, at least one suspect medicinal 
product and an identifiable reporter. The lack of any of these four elements means that the report is 
considered incomplete and does not qualify for reporting to the competent authorities. Other non-
mandatory but relevant data elements are: patient demographics (age, gender, medical history), 
drug-related information (e.g., dose, strength, start and stop date and indication), ADR-related 
information (seriousness, outcome, duration, reaction start date and end date, dechallenge and 
rechallenge) [12]. 
Spontaneous reports are collected at regional, national and international level. Relevant examples 
of international spontaneous databases are Vigibase® maintained by the WHO Uppsala Monitoring 
Center in Sweden (WHO-UMC) [13], the FDA Adverse Event Reporting System (FAERS), and the 
Vaccine Adverse Event Reporting System (VAERS) in US [14], and EudraVigilance maintained by 
the European Medicines Agency (EMA) in Europe [11]. Established in 1968, Vigibase is the largest 
database of its kind in the world, with over 15 million reports of suspected ADRs [13] worldwide. 
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Established one year later, in 1969, FAERS contained at the end of 2016 more than 8.5 milion reports 
from USA and the rest of the world, on products licensed in the USA [15], while EudraVigilance, 
has a data collection dating back to 1995 and a size of 6.7 million reports worldwide (also at the 
end of 2016) [11]. In addition to the international databases, national or regional databases exist, 
maintained by national competent authorities. Also, each marketing authorisation holder is obliged 
to have its own internal database for the products owned. Due to reporting rules, the content of the 
industry owned, regional and international databases are overlapping to some extent in terms of 
contained reports. As far as we are aware, the degree of overlap is not described in the literature and 
is very much dependent on the ADR and drug under investigation [16]. A recent study showed that, 
in some situations, small national databases can reveal signals that are not identified in the larger 
international databases [17]. The most straightforward explanation for this finding is that the ability 
to observe signals depends on the background of the database, which differs among the existing 
databases [18]. 
The spontaneous reporting systems have both advantages and disadvantages. Their advantages 
include: large catchment population, low cost, and coverage of virtually all licensed drugs [19]. The 
most important limitations are: under-, over- and duplicate reporting, missing and incomplete data, 
lack of denominator data and unknown causality [8]. Underreporting is one of the most notorious 
limitations and is very hard to overcome since nothing can be done in the absence of data. Although 
it is difficult to provide an accurate estimate of the level of underreporting, a review [20] has shown 
that it may be as large as 90%, even for serious events. Public campaigns on ADR reporting can 
increase the reporting rate, however this may also lead to skewed reporting and false positive signals 
[21].Ultimately, some researchers argued that spontaneous reports are flawed and we should look 
for better alternatives [22,23]. One of these alternatives is the electronic healthcare data2. 
Electronic healthcare records2
’Electronic healthcare records (EHRs) is an organized set of healthcare data or collection of files available 
by computer through electronic format. It is derived from a raw electronic healthcare database. EHRs 
include administrative claims and electronic medical record data’ [24]. Electronic medical records 
constitute a collection of medical records from general practitioners or specialists gathered in the 
office, clinic, or hospital and are used for diagnosis and treatment. Administrative claims data were 
the first automated databases used for population-based research and they were first established in 
North America in the 1980’s. They consist of the billing codes that physicians, pharmacies, hospitals, 
and other health care providers submit for reimbursement of costs to payers [25]. Claims databases 
usually contain information on medical procedures, and dispensed drugs from primary care, 
hospitals and pharmacies. 
2 Terminology in this area is often unclear with the term electronic healthcare records and electronic medical records often used 
interchangeably.
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In 1999, Vioxx® (rofecoxib), a non-steroidal anti-inflammatory drug, was approved and quickly 
gained popularity due to its selective mechanism of action that promised less gastro-intestinal 
haemorrhagic events. Five years later, in 2004, the drug was voluntarily withdrawn from the market 
[26]; the data safety monitoring board of the Adenomatous Polyp Prevention on Vioxx, (APPROVe) 
trial, recommended study termination due to an increased cardiovascular risk observed in the 
treated arm [27]. At the moment of withdrawal, millions of people were already exposed to the 
drug. Using actual data on the penetration of rofecoxib in the market, it has been calculated that 
if the medical records of 100 million patients would have been available for safety monitoring, the 
adverse cardiovascular effect would have been discovered in just three months after marketing [28]. 
This safety incident accelerated the investigation of alternative sources and methods for generating 
better evidence on safety of medicines in the post-marketing setting.
Initiatives started to develop in parallel in the USA and Europe. In Europe, one of the first initiatives, the 
Exploring and Understanding Adverse Drug Reactions (EU-ADR) project (2008) has created a multi-
database network of EHRs across several European countries. The databases are a mix of primary 
care and administrative databases. Within the network, several detection methods have been tested, 
some traditional ones and some invented specifically for this purpose (see further details under 
Signal detection methods) [29]. In the same year, the Observational Medical Outcomes Partnership 
(OMOP) [30] was initiated in the USA, with a similar aim: to build a network formed of administrative 
databases and on top of it an alternative surveillance system. Very much focused on the data 
mining methodology, OMOP has organized a methods competition to facilitate development and 
evaluation of novel approaches for identifying drug safety issues in EHR [31]. OMOP has empirically 
evaluated the performance of various analytical methods and established a shared resource so that 
the broader research community can collaborate. An OMOP-EU-ADR comparison showed similar 
results in terms of methods performance: self-controlled designs, achieved higher performance 
than other methods [32]. When the OMOP project ended, it transitioned to the Observational 
Health Data Sciences and Informatics (OhDSI) community, a network of researchers sharing tools 
and methods to learn from health data [30]. In 2009, the Sentinel Initiative started in the USA, with 
a legal mandate to create a new post-marketing surveillance system [33]. As of September 2017, 
Sentinel has built a distributed database covering data on more than 223 million subjects. It was 
the source of 137 assessments of products, conditions, product-outcome pairs. Although Sentinel 
initially focused on signal refinement and validation, they they recently also started to explore new 
data mining methods for EHRs, as for example the tree temporal scan data mining method [34]. 
In 2010, the public private research project Pharmacoepidemiological Research on Outcomes 
of Therapeutics by a European ConsorTium (PROTECT) [35] started in Europe. A collaborative 
project between regulators, research organisations and pharmaceutical companies, run between 
September 2009 and February 2015 and had a work package dedicated to signal detection.
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The EHRs are attractive due to their comprehensive clinical information, large coverage and their 
longitudinal dimension. In addition, they do not contain duplicates, as spontaneous reports do, 
they are not affected by under- or over-reporting and the information about exposure periods 
and clinical events is more valid and complete [36]. Despite these advantages, the EHRs are 
methodologically challenging for signal detection, as they were not built with this objective in mind. 
Hypothesis-free exploration is a secondary use for these data sources. Since they do not contain the 
presumed causality inherent in the spontaneous reports, the found associations are more prone to 
confounding. This could be solved by proper adjustment, unfortunately it is limited by the lack of 
information on lifestyle factors (main confounders) in many databases. Another limitation of EHRs 
is the lack of validation of diagnostic coding. In case of multi-database networks, heterogeneity in 
database structure, language and coding of drugs and diseases add to the challenges [37]. 
Signal detection methods
Signal detection started with the manual review of individual spontaneous case reports by trained 
medical professionals [38]. This method is still applied and may be very effective when numbers 
of cases are not too large. In 1960, in Canada, Ed Napke developed a system to collect and classify 
ADRs, the so -called the ‘pigeonhole system’ [39]. This system contained a storage unit with many 
small compartments, classified according to the drug and the reported reaction in which the reports 
were stored. In this way, it was easier to observe an increase in a certain type of reports. Afterwards, 
in 1974, Finney suggested statistical approaches for observing signals of ADRs [40]. He introduced 
the idea of using a 2×2 table for comparing the proportion of reports for a particular drug suspected 
for a certain ADR with the proportion of that reaction observed with the other drugs from the 
database (see Figure 2). This concept was named by Finney ‘reaction proportion signalling’ and was 
later updated and refined by Evans and renamed as ‘proportional reporting ratio (PRR)’ [41], a term 
which is established and still used nowadays.
Disproportionality analysis, as conceived by Finney and Evans, is the classical statistical approach to 
detect signals in large spontaneous databases and consists of calculating an observed-to-expected 
events ratio. The observed-to-expected ratio establishes if a specific ADR-drug combination is 
reported more frequently than expected in the untreated population. This ratio is based on an 
‘artificial denominator’ since in spontaneous reporting systems there are no untreated patients, 
only patients treated with other drugs which experienced a certain ADR. These patients form the 
denominator, see Figure 2 [42]. 
The most common disproportionality methods are: PRR [41] and reporting odds ratio (ROR) [43], see 
Table 2. Their estimates are easy to calculate, however the results tend to become unstable when 
the number of events is small, resulting in potentially high estimates with wide confidence intervals. 
This instability led to the development of more advanced detection techniques based on Bayesian 
statistics. The Bayesian techniques try to adjust for uncertainty in the data by shrinking the estimates 
depending on the amount of data available [44]. The commonly used Bayesian methods are the 
Multi item Gamma Poisson Shrinker (MGPS) [44] and the Bayesian Confidence Propagation Neural 
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Network (BCPNN) [45]. An overview of the most common used methods and their calculation is 
presented in Table 1. 
Users of a particular drug
Users of a particular drug who experience an ADR
Users of a particular drug who experience an ADR
which is reported in the database
Adverse event 
of interest
A
C
a+c
Other adverse 
events
B
D
b+d
Total 
a+b
c+d
a+b+c+d
Drug of interest
All other drugs*
Total
A BCD
Figure 2: A 2x2 contingency table for a drug-adverse event combination, in spontaneous reporting 
databases3
*Drugs may be reported as suspected or as concomitant medication.
Table 1: An overview of the common methods in signal detection
Name Point estimate Confidence interval Institutions 
which use it
Advantages and 
Disadvantages
Frequentist methods 
ROR ad/bc EMA, MEB (+) Easy to apply and 
interpret 
(–) Higher rate of false 
positives
(–) Unreliable at low 
numbers 
PRR a/(a+b)/c/(c+d)
Bayesian methods
IC* a(a+b+c+d)
(a+c)(a+d)
log
2
WHO (+) Higher specificity
(–) Lower sensitivity 
(–) Harder to apply 
and interpret 
EBGM a(a+bc+d)
(a+c)(a+d)†
FDA, MHRA
BCPNN=Bayesian Confidence Propagation Neural Network; EBGM=Empirical Bayes Geometric Mean; IC=Information component; 
PRR=Proportional reporting ratio; ROR=Reporting Odds Ratio; 
* based on BCPNN aproach [45]
† Complex formula, not entirely reproduced above. It is based on the Multi item Gamma Poisson Shrinker [46]
3 Adapted from Poluzzi Elisabetta ER. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA 
Adverse Event Reporting System (AERS), PhD thesis. 2012.
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With regards to the signal detection methods applied to EHR, one option is to fit the EHR database 
into a spontaneous reports data structure and use the disproportionality methods presented above. 
However, the disproportionality methods are ‘cross-sectional’ and they do not take into account the 
longitudinal dimension of the data. Therefore, the second option is to use detection methods that 
can incorporate the longitudinal dimension of EHRs. One such example is the Longitudinal Gamma 
Poisson Shrinker (LGPS). LGPS is an adaptation of the Bayesian Gamma Poisson Shrinker but uses 
person time rather than case counts for the estimation of the expected number of events [47]. In 
this method, the incidence rate ratio for a ADR during treatment with a specific drug is calculated by 
multiplying the duration of exposure with the incidence ratio for the ADR when not exposed [47]. 
An underlying assumption here is that the risk does not vary with the time. 
Another way to incorporate longitudinal information in the analysis is to use an extension/
adaptation of traditional epidemiological designs as: new user cohort [48], case control [49] or the 
self-controlled case series method [50]. These designs compare the incidence rate of the ADR during 
exposed time with the incidence rate during unexposed time. Since both designs use a comparator 
group to estimate the incidence rate, between-person confounding is an issue to be addressed 
when using these methods. 
Also borrowed from the pharmacoepidemiology field, the ‘self-controlled case series’ [51] estimate 
the drug-ADR association using only information on cases. Each case acts as its own control, 
automatically adjusting for between -person confounding. This method is widely used for studying 
safety of vaccines that are administered to large cohorts and for which it is hard to find an unvaccinated 
group as comparison [50]. Temporal pattern discovery is another ‘self-controlled method‘ specifically 
created for EHRs, invented by Noren et al. [52]. The objective is to identify interesting or unusual 
temporal patterns between the occurrence of an event and the administration of a prescribed drug. 
These unusual occurrence patterns are an indication for a potential signal. Again, only information 
on cases is used. 
A full range of methods designed for data mining in EHR were tested and described by Schuemie [29]
and Ryan [53]. 
The PROTECT initiative in Europe explored signal detection methods tailored to EHRs [19]. Their 
analysis was performed in The Health Improvement Network (THIN) database of longitudinal 
electronic health records from general practices in the UK [20], where they implemented a self-
controlled cohort analysis with temporal Pattern Discovery [21]. The method identifies outcomes 
which have increased rates soon after initiation of treatment (temporally associated). The tested 
method was more conservative than the epidemiological studies, highlighting a lower number of 
drug adverse event pairs [22].
In the other project, the PROTECT group has explored the use of different medical term groupings 
when mining the database and use of subgrouping and stratification techniques in signal detection. 
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They also compared the existing signal methods across a wide range of databases to find out which 
one performs better and under which circumstances [35]. Based on the work done by PROTECT, 
changes were introduced in 2016 in signal management activities in Europe: the change of of 
statistical measure from PRR to ROR, change of applied thresholds, stratification by age groups 
and by region where reports originated [54]. Preliminary analyses have shown that these changes 
increase performance of the signal detection process [55].
Statistical signal detection methods function like a diagnostic system that needs to discriminate 
between true and false signals. The performance of methods is measured by this discrimination 
capacity. Ideally, the signal detection methods will be highly sensitive (e.g., identifying all existing 
signals) and at the same time highly specific (e.g., correctly dismissing all the false associations). 
Unfortunately, improving both sensitivity and specificity at the same time is not possible without 
incorporating extra information in the methods and since available information is usually limited, a 
trade-off between specificity and sensitivity needs to be made. Due to the cautionary approach in 
pharmacovigilance, a premium is put on sensitivity over specificity, e.g., we prefer to pick as many 
signals as possible with the cost of having more false positives. Many studies have compared the 
performance of statistical signal detection methods. In general, performance is similar, except when 
the number of reports is very low [56,57]. The implementation of methods in a specific database 
seems to be important for performance. Some of the implementation decisions that influence 
performance are: the type of database; including suspect or suspect and concomitant drugs in the 
denominator; choice of reference groups; control for confounding; level of hierarchy within the 
medical dictionary and choice of threshold and precision estimate [58]. 
Signal prioritisation
A third area in signal management that can benefit from further research and evidence based 
recommendations is signal prioritisation. Prioritisation is a decision-making process aimed to focus 
attention on signals with a high likelihood to be real and with a high public health impact, while at 
the same time discards the false positive signals. Prioritisation is necessary in signal management 
due to the high number of potential signals generated by data mining [59] and helps allocation of 
resources in the most optimal way. 
During prioritisation, clinical, pharmacological and regulatory data are evaluated and weighted 
and a variety of variables can be considered as prioritisation factors. However, there is no general 
consensus as to how prioritisation should be done, mainly because different variables might have 
different importance depending on the evaluated signal. The Implementing Regulation mentions 
three prioritisation factors: the novelty of the drug, the strength of the association and the 
seriousness of the reaction [9]. The CIOMS report also mentions the novelty of the drug, seriousness, 
and in addition, a high and rapidly increasing disproportionality score [8]. Standardization of the 
prioritisation process, by using already constructed prioritisation frameworks, might help reduce the 
subjectivity. A summary of the main existing prioritisation tools is presented below. 
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The Regulatory Pharmacovigilance Prioritisation System has been developed, validated and 
implemented within the UK national competent authority. It prioritises signals according to four 
categories of factors: health consequences, strength of evidence, regulatory obligations and public 
perceptions. A second prioritisation tool, multi criteria decision analysis (MCDA) was developed by 
Levitan et al. [58] and takes into account medical impact (50% weight), strength of evidence (40% 
weight) and novelty of event (10% weight). The model was tested against expert group judgment 
and the agreement between the model and expert opinion was found to be moderate. A third 
instrument is the vigiRank model developed by Caster et al. [59], a prioritisation algorithm that 
accounts mainly for reports quality and content. The variables considered for inclusion capture 
different aspects of strength of evidence, focusing on quality and clinical content of individual 
reports, as well as trends in time and geographic spread. Public health impact was not considered 
by this algorithm. Finally, Coloma et al. [27] published a prioritisation exercise, albeit based on signals 
for EHRs, considering public health importance, novelty and biologic plausibility. 
Once the prioritisation is complete, further signal strengthening and assessment is conducted and 
a recommendation for action is taken accordingly. The recommendation for action is more often 
an update of the product information with the newly discovered ADR. But actions can range from 
conducting additional studies to direct communication to healthcare professionals or even product 
withdrawal. 
AIMS AND OUTLINE OF THIS THESIS
This thesis aims to present an overview of the current signal management process and explore 
how this may be improved from a scientific and a regulatory perspective, addressing especially 
three previously identified key areas: data sources, methods for detection and prioritisation. The 
work described in this thesis is based on various data sources both European and US based, mostly 
spontaneous reporting systems but also EHRs, as presented in Table 2. 
Table 2: Summary of data sources used in this thesis 
Chapter Topic Data source Type Setting Size Inception 
year
Chapter 3.1 Signal detection EU-ADR Network of electronic 
healthcare record 
databases
Denmark, Italy, 
Netherlands, UK
~30 million 
patients
2008
Chapter 3.1/6 Signal detection 
and prioritisation
Eudra-
Vigilance
Spontaneous 
reporting database
Worldwide* ~6.7 million 
cases
1995
Chapter 3.2 Signal assessment THIN Electronic medical 
records; primary care
UK ~15.6 million 
patients
2002
Chapter 4 Signal detection FAERS Spontaneous 
reporting database
US ~9 million 
cases
1969
* Under the condition that the drug associated with the ADR has marketing authorisation in Europe; EU-ADR=Exploring 
and Understanding adverse drug reactions; FAERS=FDA Adverse Event Reporting System; THIN=The Health Improvement 
Network; UK=United Kingdom.
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The thesis is divided into seven chapters. The first chapter provides a general introduction and 
context to the pharmacovigilance field. In Chapter 2 we provide an overview of the signal detection 
process in Europe; we describe the safety signals brought to the PRAC during the first 18 months of 
its operation and the actions taken in relation to those. 
In Chapter 3 we explore the use of EHRs in signal management. Firstly, as a tool for generation of 
new signals. The aim was to investigate in which particular situations EHR-based signal detection 
systems may provide an added value to spontaneous reporting systems, focusing on a limited set of 
adverse events of considerable importance in pharmacovigilance. Secondly, we explore EHR use for 
validation/assessment of existing signals, through hypothesis testing exercises. We chose to study 
the association between triptans and ischemic colitis, a signal that led to a regulatory action (update 
of the product information) but remained to be evaluated by a pharmacoepidemiological study. In 
Chapter 4 we investigate if the performance of signal detection could be improved through age 
stratification and adjustment, with a special focus on paediatric signal detection.
In Chapter 5 we provide an overview of the current prioritisation criteria as well as a brief description 
of their validity and performance. In Chapter 6 we explore a more risk-based monitoring, based on 
the usage of the drug before and after authorization. We test the hypothesis that the number of 
patients exposed to the drug is a predictor of how quickly safety issues will be identified for that 
product in the initial period after authorisation. 
Finally, in the last chapter, Chapter 7, a summary of findings, discussion and future perspectives are 
presented, as well as derived recommendations. 
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ABSTRACT
Background and Objectives: New pharmacovigilance legislation in the EU has underlined the 
importance of signal management, giving the European Medicines Agency’s newly-established 
Pharmacovigilance Risk Assessment Committee (PRAC) the mandate to oversee all aspects of use 
of medicinal products including detection, assessment, minimization and communication relating 
to the risk of adverse reactions. In this study we describe the signals as brought to the PRAC during 
the first 18 months of its operation and the ensuing regulatory actions. 
Methods: Data was collected from publicly available sources, for the period September 2012–
December 2013, classified according to predefined rules and described using the appropriate 
descriptive statistics. Suspected adverse drug reactions (ADRs) were categorized using the Medical 
Dictionary for Regulatory Affairs (MedDRA) terms and drug names were mapped to the Anatomical 
Therapeutic Chemical (ATC) codes. 
Results: During the study period, 125 signals concerning 96 medicinal products were discussed by 
the PRAC. The majority of signals were triggered by spontaneous reports (72%) and the median drug 
age (since marketing authorization) for drugs that prompted a signal was 12.3 years, significantly 
less compared to drugs that had no signal within the same period (19.7 years). The mean time until 
a decision was reached by PRAC was 2.5 months, with 42.8% of all decisions taken during the first 
meeting. The decisions to start a referral and to send a direct healthcare professional communication 
took the least amount of time (1.8 months and 1.7 months, respectively).
Conclusions: The importance of spontaneous reporting in signal detection and monitoring of safety 
issues throughout the entire lifecycle of a medical product is confirmed by our study. The new role 
of the PRAC contributed to a better coordination of real-time signal management via more prompt 
assessment and decision-making. If sustained, this may well optimize the safe and effective use of 
medical products.
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INTRODUCTION 
Pre-approval clinical research is primarily focused on establishing efficacy and its limitations with 
regards to identifying risks are well known and described previously [1-3]. Only after market exposure 
and use in every day practice more information on the full benefit risk profile will be identified. 
An important cornerstone in further clarifying the risk profile of a medical product post-marketing 
is the detection of ‘signals’, that is, ‘information which arise from one or multiple sources (including 
observation and experiments), which suggest a new potentially causal association or a new aspect of a 
known association, between an intervention and a set of related events, either adverse or beneficial, which 
would command regulatory, societal or clinical attention, and is judged to be of sufficient likelihood to 
justify verificatory action’ [4]. In pharmacovigilance we are primarily concerned with safety signals. 
Safety signals may arise anytime during the drug lifecycle but they are expected to occur more 
frequently in the first years of marketing [4]. However, also after several years new adverse events 
can arise. 
Within the context of the new pharmacovigilance legislation in the European Union (EU), this key 
initial stage in the pharmacovigilance process is now duly recognized and specific responsibilities 
and interactions between stakeholders have been laid down in several guidance documents [5,6]. 
According to the current legislation, the marketing authorization holders, the European Medicines 
Agency (EMA) and national competent authorities ‘should continuously monitor the data available in 
the EudraVigilance database‘ [6,7].
The PRAC [8] at the EMA has a central role in scientific advice and decision making in relation to 
signal management. The mandate of the Pharmacovigilance Risk Assessment Committee covers 
all aspects of the risk management of the use of medicinal products for human use including the 
detection, assessment, minimisation and communication relating to the risk of adverse reactions, 
having due regard to the therapeutic effect of the medicinal product for human use, the design 
and evaluation of post-authorization safety studies and pharmacovigilance audit [6,7,9]. For signal 
management, the PRAC has an important role in the prioritization of potentially new safety issues, 
evaluating the underlying data and making recommendations regarding the regulatory actions that 
should be taken [5,9]. 
OBJECTIVES AND HYPOTHESIS
The objective of this study was to characterize the signals as brought to the PRAC during the first 
18 months of its operation (September 2012–December 2013) and the ensuing regulatory actions. 
Within this characterization we focused on factors related to the lifecycle of a drug (e.g., time since 
marketing authorization). 
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METHODS
Data collection 
Data regarding the safety signals was extracted from the publicly available information on the 
website of the EMA containing PRAC meeting minutes and recommendations on safety signals 
[10,11]. Suspected adverse drug reactions (ADRs) were categorized using the Medical Dictionary 
for Regulatory Affairs (MedDRA terminology, version 16.1), an international medical terminology 
developed under the auspices of the International Conference on Harmonization (ICH) [12]. 
International nonproprietary names of drugs were mapped to the Anatomical Therapeutic Chemical 
(ATC) codes according to the World Health Organization (WHO) classification and first authorization 
date was collected from the European Union Reference Date (EURD) list, when not available from 
the EMA website or other regulatory resources. For class effects, the oldest substance was used as a 
reference for calculating the time since marketing authorization. Data on medical product exposure 
was likewise obtained from PRAC meeting minutes. 
Classification of variables 
Signals are classified, by default, to be derived from either EU spontaneous reporting systems 
(Eudravigilance or national) or other sources. However, in order to provide more detailed information 
on the source of the signals, we employed the following classification for this study: (1) spontaneous 
case reports; (2) clinical trials; (3) observational studies; (4) published case reports or case-series; and 
(5) others (see Figure 1). 
Signals with a mixed source: spontaneous and published case reports were classified as spontaneous. 
Communications from other regulatory authorities outside the EU were tracked, when possible, in 
order to determine the original signal source. The medical products were classified according to 
the type of authorization: centralized authorization (i.e., single marketing authorization across all EU 
countries) or national authorization (i.e., the product is authorized at a national level in one or more 
member states). 
PRAC recommendations were collected and categorized according to the action taken. After a signal 
is brought to the PRAC for discussion, these are the possible outcomes: (1) no action; (2) request for 
further data; or (3) immediate action. Further evaluation in an ongoing periodic safety update report 
(PSURs) assessment was considered a separate and temporary outcome. The recommendation for 
cumulative reviews to be provided in future PSURs was considered routine pharmacovigilance. 
The regulatory actions that can be taken after a signal is discussed include: (1) update of summary 
of product characteristics (SmPC and PL); (2) direct communication to healthcare professionals; 
(3) update of the risk management plans; (4) suspension/withdrawal from the market; or (5) re-
evaluation of benefit risk profile through a referral procedure. It is possible to have more than one 
regulatory action per signal. In this study, we considered an action as immediate if the decision was 
taken in the first PRAC meeting. Signals for which the outcome was not available in the month after 
the end of our study period (i.e., January 30, 2014) were labeled as ongoing. 
519883-L-sub01-bw-Pacurariu
Processed on: 5-6-2018 PDF page: 31
Signal detection in Europe: current status
31
2
Evaluated signals*
n=95
Routine pharmacovigilance
33
SmPC update
51
RMP update
7
Issue of DHPC
7
Referral started
9
13 signals  adressed in paralel
PSUR procedures
17 signals  Ongoing 
Figure 1: Workflow of signals at PRAC
SmPC=Summary of Product Characteristics; RMP=Risk Management Plan, DHPC=Dear Healthcare Professional 
communication; PSUR=Periodic Safety Update Report/ *More than one recommendation per signal possible
Data analysis 
Descriptive statistics appropriate to the type of variables were used to describe the characteristics of 
signals discussed at PRAC during the study period. 
We also tested the hypothesis that drugs that had signals in the study period were ‘younger’ than 
those that did not have signals. For this purpose we compared the drugs which had at least one 
signal on the PRAC agenda during the study period with a set of controls that were drugs monitored 
during the same period but that did not yield any signal considered at PRAC. These controls were 
chosen from the signal work-sharing list [13] and from the list of centralized products monitored 
by the EMA. In the case of signal work-sharing list, to correct for potential variations in applying 
monitoring methodologies between countries, drugs were matched on Lead Member State (i.e., 
country responsible for monitoring of a particular drug) to ensure that they underwent the same 
screening process. 
RESULTS
During the study period September 2012–December 2013, PRAC 125 signals were discussed 
by PRAC, for 96 different drugs. Among the 125 signals, 15 were follow-ups from the previous 
Pharmacovigilance Working Party (i.e., former scientific group that handled signals at EMA before 
establishment of PRAC) discussion. 
A descriptive analysis of all signals discussed at PRAC is presented in Table 1. The majority of signals 
were triggered by spontaneous reports (72%), followed by clinical trials (8%) and observational 
studies (8%). Ten signals (8%) originated from regulatory authorities outside Europe. The most 
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frequently discussed signals were related to skin and subcutaneous tissue disorders (12.8%), nervous 
system disorders (10.4%), cardiac disorders (6.4%) and immune system disorders (6.4%). 
Table 1: Characteristics of signals discussed at PRAC September 2012–December 2013
Variables 
Signals count 125*
Medicinal products count 96
Identifier count (%)
European Medicines Agency 65 (52.0%)
Individual Member States 
The Netherlands 15 (12.0%)
United Kingdom 15 (12.0%)
Other 30 (24%)
Italy 7 (5.6%)
Sweden 5 (4.0%)
France 4 (3.2%)
Time since marketing authorization years (%)
Median (range) 12.3 (0.54–67.9)
≤5 years 20 (21.1%)
5-10 years 20 (21.1%)
≥10–15 years 16 (16.8%)
≥15 years 39 (41.0%)
Type of authorization† count (%)
Centralized 49 (51.0%)
National 41 (42.7%)
Mixed 6 (6.3%)
Signals of special interest count (%)
Drug Interaction 13 (10.6%)
Medication error 2 (1.6%)
Off-label use 2 (1.6%)
In utero exposure 2 (1.6%)
Accidental exposure 1 (0.8%)
Source, count (%)
Spontaneous cases 90 (72.0%)
Randomized controlled trials 10 (8.0%)
Observational (post marketing) studies 10 (8.0%)
Literature case reports 8 (6.4%)
Other 7 (5.6%)
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Table 1: Continued
Variables 
EU spontaneous reporting systems 94 (87%)
Other sources 14 (13%)
System Organ Class‡, count (%)
Skin and subcutaneous tissue disorders 16 (12.8%)
Nervous system disorders 13 (10.4%)
Cardiac disorders 8 (6.4%)
Immune system disorders 8 (6.4%)
Blood and lymphatic system disorders 7 (5.6%)
Investigations 7 (5.6%)
Vascular disorders 7 (5.6%)
Other 59 (47.2%)
Drug class, count (%)
Antineoplastic and Immunomodulators 25 (26%)
Nervous system 20 (20.8%)
Anti-infective for Systemic Use 13 (13.5%)
Alimentary Tract And Metabolism 5 (5.2%)
Other 33 (34.4%)
ATC=anatomic therapeutic chemical classification. *Three signals were not counted for the following reasons: two were 
considered a duplication of the same signal for a different vaccine strain (primary ovarian failure and complex regional 
pain syndrome with HPV vaccines) and another one (boceprevir and drug interaction with quetiapine) was extended 
(considered class effect) from an already discussed signal. †Centralized authorization=a single marketing authorization 
that is valid in all European Union countries, National authorization=the product is authorized and marketed in one 
or more member state(s), Mixed=a combination of centralized and national authorization; ‡System Organ Class= 
classification of an adverse reaction according to its etiology and manifestation site in MedDRA terminology.
The median time since the first marketing authorization in a European country for the drugs 
discussed at the PRAC was 12.3 years (range=0.5–67.9), with 42.2% being less than 10 years on the 
market (see Figure 2). 
Exposure data was available for 75% of drugs, however it was variously reported as either number 
of patients (42%) or person-years (33%) and across different time periods and therefore not directly 
comparable between drugs. From the comparable data, the median cumulative exposure since 
marketing authorization until signal date was 2.1 million patients (range=0.003 to 320 million 
patients), the majority of drugs (67.6%) having an exposure of less than 10 million patients. 
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Figure 2: Time since marketing authorization across drugs that had a signal on the PRAC agenda
Table 2 summarizes PRAC final recommendations regarding signals and the mean time from first 
discussion until decision. Signals under ongoing evaluation (n=17, 13.6%) and those addressed in 
parallel procedures were excluded from the time analysis since no final outcome was reached for 
those at the time of writing of this article. The mean time-to-PRAC decision for a signal was 2.5 
months (95%CI=2.0–3.2) with 42.8% of all decisions taken during the first meeting (i.e., immediate 
action). We performed a sensitivity analysis where we included the decision to address the signals in 
ongoing PSURs in the calculation; for this we obtained a mean time-to-PRAC decision of 2.2 months 
(95%CI=1.7–2.7) with 53.8% immediate actions taken. 
The decisions to start a referral and to communicate a safety issue via direct healthcare professional 
communication took the least amount of time (1.8 months and 1.7 months, respectively). These 
results should be considered in the context of the fact that PRAC conducts meetings on a monthly 
basis. 
For 57.2% of the signals, additional information was requested after the first discussion in the PRAC 
either from marketing authorization holders via a cumulative review (n=65) or from member states, 
in the form of non-urgent information request (n=8). The cumulative reviews were submitted either 
within 30 or 60 days, or addressed during an ongoing periodic safety updates report procedure (see 
Figure 3). 
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Data requested from MAH 87%
Data
requested
from
Member
States
   10%
Request of
pharamaco-
epidemiological
studies 3%
Cumulative Review 60 days
Cumulative Review in PSUR
Cumulative Review 30 days
Other deadlines
65%
20%
12%
3%
Figure 3: Type of additional information requested during signal assessment at PRAC. 
MAH=Marketing authorisation holder, PRAC=Pharmacovigilance Risk Assessment Committee; PSUR=Periodic Safety 
Update Report 
In the second part of the study, the hypothesis that drugs with signals are ‘younger’ (i.e., have been 
on the market more recently) on average than drugs without signals was tested. The comparison 
between drugs with signals (n=96) and without (n=894) at the end of the monitoring period 
showed that the drug age was significantly lower for drugs that had identified safety issues in the 
period (median=12.3 vs. 19.7 years, p=0.01, Mann-Whitney U test).
DISCUSSION
At the time of approval, knowledge of the full benefit-risk profile of any new drug is incomplete due 
to well-known limitations of pre-approval research. Throughout a drug’s lifecycle, (serious) safety 
issues may emerge and while market approval may mark the end of drug development, it also 
marks the start of continuous evaluation of benefits and risks. The results of our study reaffirm the 
important role of spontaneous reporting in detection of signals and continuous need for monitoring 
since safety issues are also identified later in the life cycle of a drug. 
For the interpretation of the results, it is important to keep in mind that the signals discussed at PRAC 
and hence considered in our study represent only a subset of all signals discussed in the regulatory 
framework.
The most frequent source of signals discussed by the PRAC was spontaneously reported ADRs (72%). 
This is in line with studies from the United States [13], where spontaneous reports were also found to 
be the most frequent source. Within signals from spontaneous sources, 10.6% of them had multiple 
origins: spontaneous reports and literature, while another 6.5% were identified exclusively from 
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published case reports, which emphasizes the importance of continuously monitoring scientific 
publications [3,14]. For a few signals arising from spontaneous reports, the evidence was based on 
one single case report (e.g., nomegestrol acetate-deep vein thrombosis, human papillomavirus 
vaccine-bronchospasm and erlotinib-pancreatitis).
The drug age in our study was significantly lower for medicines with a signal as compared to those 
without (median=12.3 vs. 19.7 years, p=0.01). Two papers regarding Food and Drug Administration 
(FDA) safety-related drug label changes reported that the safety actions occurred at a median of 
11 [15], and 10 years [16] after initial approval, similar to our results. Another paper investigating 
regulatory actions for biologicals reported the mean time to a safety related regulatory action to 
be 3.7 years [17]. This shorter time is probably explained by the fact that this study only included 
biological drugs, which have an essentially different safety profile and are thus more intensively 
monitored post-marketing via post-authorization safety studies and/or registries. 
While signals occur more frequently for younger drugs (see Figure 2), safety issues still appear for 
drugs that have been on the market for more than 50 years (e.g., cloroquine, thiopental, codeine, 
and triamcinolone). 
This is probably due to change in patterns of utilization for these drugs, better implementation 
of safety monitoring, increased awareness in relation to certain safety issues as well as finalization 
of long-term observational studies. Such an example is the signal for codeine and life-threatening 
toxicity in CYP2D6 ultra-rapid metabolizers, a safety issue which only occurs in a small sub-
population. The findings in our study are in line with the results of Mol et al. who showed that 
27% of serious safety issues were communicated to healthcare professionals ten or more years after 
approval [18]. Another contributing factor to the identification of signals for old drugs is that some 
signals are not new from a scientific point of view but they can appear to be so from a regulatory 
perspective (e.g., when a certain adverse reaction is listed in the summary of product characteristics 
in some countries but not in others). 
The most frequent recommendation was a change in the product information and this is similar to 
what has been reported in relation to the post-marketing safety surveillance decisions taken in the 
US [13,19]. 
The mean time from signal the identification until a PRAC decision was taken 2.4 months. A 
timeframe of 21 months from signal detection to action has been reported by Hochberg et al. [20] 
for the FDA’s system, although the data are not directly comparable, since there is also a time-lapse 
between decision and actual implementation, which we did not take into account. 
According to our analysis, the PRAC decision making process is efficient; especially in case of 
serious concerns leading either to referral or DHPC dissemination, which were handled even more 
expeditiously (see Table 2). This is in line with a recent study that described the PRAC activities since 
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its initiation and reported some process indicators which showed that the system is more structured, 
faster and with a more risk-proportionate approach [9]. 
A limitation of our work might be that only signals discussed at PRAC were considered, although there 
are other regulatory pathways through which signals can be handled (e.g., PSURs) so we analyzed 
only a fraction of the available information. Limited availability and heterogeneity of exposure data 
precluded further analysis of this variable, therefore we recommend increased standardization in 
its reporting, although we acknowledge the difficulties of acquiring accurately consistent exposure 
data at the European level. 
In conclusion, the importance of spontaneous reporting in signal detection and monitoring of 
safety issues throughout the entire lifecycle of a medical product is confirmed by our study. The 
new role of the PRAC contributed to a better coordination of real-time signal management via more 
prompt assessment and decision-making. If sustained, this may well optimize the safe and effective 
use of medical products.
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ABSTRACT 
Background and Objectives: Spontaneous reporting systems (SRSs) remain the cornerstone 
of post-marketing drug safety surveillance despite their well-known limitations. Judicious use of 
other available data sources is essential to enable better detection, strengthening and validation of 
signals. In this study we investigate the potential of electronic healthcare records (EHRs) to be used 
alongside SRS as an independent system, with the aim to improve signal detection. 
Methods: A signal detection strategy, focused on a limited set of adverse events deemed important 
in pharmacovigilance, was performed retrospectively in two data sources: (1) EU-ADR database 
network and (2) EudraVigilance database using data between 2000 and 2010. Five events were 
considered for analysis: (1) acute myocardial infarction (AMI); (2) bullous eruption; (3) hip fracture; 
(4) acute pancreatitis; and (5) upper gastrointestinal bleeding (UGIB). Potential signals identified 
in each system were verified using current published literature. The complementarity of the two 
systems to detect signals was expressed as percentage of unilaterally identified signals out of the 
total confirmed signals. As a proxy for the associated costs, the number of signals that need to be 
reviewed to detect one true signal (number needed to detect: NND) was calculated. The relationship 
between background frequency of events and capability of each system to detect signals was also 
investigated.
Results: The contribution of each system to signal detection appeared to be correlated with the 
background incidence of the events, being directly proportional to the incidence in EU-ADR and 
inversely proportional in EudraVigilance. EudraVigilance was particularly valuable in identifying 
bullous eruption and acute pancreatitis (71% and 42% of signals correctly identified from the total 
pool of known associations, respectively) while EU-ADR was most useful in identifying hip fractures 
(60%). Both systems contributed reasonably well in identification of signals related to UGIB (45% in 
EudraVigilance, 40% in EU-ADR), but only fairly for signals related to AMI (25% in EU-ADR, 20% in 
EudraVigilance). The costs associated with detection of signals were variable across events; however, 
it was often more costly to detect safety signals in EU-ADR than in EudraVigilance (median NND=7 
vs. 5). 
Conclusions: An EHR-based system may have additional value for signal detection, alongside already 
established systems, especially in the presence of adverse events with high background incidence. 
While SRS appeared to be more cost-effective overall, for some events the costs associated with 
signal detection in EHR might be justifiable. 
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INTRODUCTION 
Spontaneous reporting systems (SRSs) have long been the foundation of post-marketing drug safety 
surveillance [1]. Despite their broad utilization, information found in such systems is sometimes 
limited [2] and as a consequence, decisions based solely on data from these systems often need to 
take into account significant uncertainties [3]. In many instances it is not sufficient to use a single 
source of information to understand a particular drug safety issue [4] and there is a recognized need 
to put together, in an efficient way, most, if not all, available relevant sources. 
Following the drug safety concerns surfacing between 2004 and 2007, many discussions started 
whether we can have a more pro-active approach to signal detection instead of relying on passive 
surveillance systems. Both in Europe and the USA it was explored whether electronic healthcare 
record (EHR) databases that comprise detailed data collected longitudinally and routinely in actual 
care for large scale populations [5] may be used for post-marketing safety surveillance. EHRs have 
been primarily used for signal evaluation studies; however, in recent years, various projects have 
explored ways of using them as an additional source for signal detection systems, e.g. OMOP [6,7]
PROTECT [8] and EU-ADR [9,10]. 
To date, only two studies [11,12] have tried to combine both sources in order to support the signal 
detection process, while the majority of the available research focused rather on comparing the two 
systems in terms of overall performance and usefulness [13-16]. 
The aim of this study was to investigate in which particular situations EHR-based signal detection 
systems may provide an added value to already existing SRS, focusing on a limited set of adverse 
events of considerable importance in pharmacovigilance. To express this added value, we used 
performance indicators, including percentage of unilaterally identified signals and sensitivity to 
describe the “gains” as well as number NND for the “costs” associated with signal detection.
METHODS
Design 
A signal detection strategy focused on a limited set of adverse events was performed retrospectively 
in two database systems: (1) EU-ADR and (2) EudraVigilance from January 1, 2000 to January 1, 2010. 
These are described separately below. The two systems were considered individually and the most 
sound event definitions possible and implementation of signal detection methods were taken into 
account in each database independently in order to optimize the performance of each. In this study 
we used the term “signal” to refer to a signal of disproportionate reporting (SDRs) as defined in CIOMS 
VIII [1] in the context of signal detection in EudraVigilance and equivalent to a statistically significant 
drug-adverse event association which meets a specific threshold of increased risk in the context of 
EU-ADR. All drugs captured in either of the two systems were considered. Drugs not identifiable at 
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the fifth level of the WHO Anatomical Therapeutic Chemical (ATC) classification system, as well as 
herbal supplements, were excluded.
Events of interest
We considered the following five events, selected from a list of events previously identified as 
important based on expert judgment and predefined criteria [17]: (1) acute myocardial infarction 
(AMI); (2) bullous eruption (BE); (3) hip fracture; (4) acute pancreatitis; and (5) upper gastrointestinal 
bleeding. These events were chosen because of their diversity in etiology, background incidence, 
and drug-attributable risk -attributes which we consider might impact the performance of the two 
systems. To investigate the possible correlation between the signal detection performance of each 
system and the frequency of the events, we ranked our events of interest according to empirically 
determined background frequency (i.e., incidence rate in the general population). These incidence 
rates were derived from the EU-ADR network, in order to maintain the same base population across 
events, which allowed for a more meaningful comparison [9]. 
SRS: EudraVigilance
As exemplar for SRS, we used EudraVigilance, a web-based information system launched in December 
2001 and designed to manage information on suspected adverse drug reactions (ADRs) which are 
reported for drugs licensed in Europe. The total number of individual reports as of December 2013 
was 4.5 million, with 38% cases originating from the EU and 62% from the rest of the world [18]. 
Capturing events of interest
In EudraVigilance, suspected ADRs are coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®), an international medical terminology developed under the auspices of the International 
Conference on Harmonisation (ICH) [19]. For capturing the events of interest we used adapted 
searches derived ad hoc from standardized MedDRA® queries, [20] similar to the approach used by 
Patadia et al. [16]. 
Method of signal detection 
Signal detection in EudraVigilance was performed using the proportional reporting ratio (PRR) 
method [21], previously validated in this database by Alvarez et al. [22]. Only cases received within 
the study period (January 1, 2000 to January 1, 2010) were considered for identification of signals. 
The threshold chosen to define a signal was a lower limit of the confidence interval of the PRR 
greater than 1 together with at least 3 cases reported with the investigated association [23]. No 
further adjustment was done for possible confounding variables. 
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EHR-based system: EU-ADR 
As exemplar for EHR, we used EU-ADR, a computerized system designed to detect potential ADRs 
and built on a network of established databases from various European countries [9]. Data from 
seven databases in three countries (Denmark, Italy, the Netherlands) were used in this study. EU-
ADR includes both population-based primary care databases (Integrated Primary Care Information 
database (IPCI, Netherlands), Health Search/CSD Patient and Pedianet (Italy)), and record-linkage 
systems (Aarhus University Hospital Database (Denmark), the PHARMO Network (Netherlands), and 
the regional Italian claims databases of Lombardy and Tuscany). The source population covered by 
the database network is approximately 20 million patients. Drug exposure in EU-ADR was identified 
from prescription or dispensing data (depending on the database) using ATC codes. Prescriptions 
with the same ATC code where the start date of one prescription precedes the end date of the 
other prescription were merged into a single episode of drug use, starting at the beginning of the 
first prescription, and ending at the end of the last prescription. Periods of concomitant drug use 
were labelled as separate episodes. Only current exposure (within 30 days of an event of interest) 
was considered [9]. The characteristics of the EU-ADR network have been extensively described 
elsewhere [9,24]. 
Capturing events of interest
Definitions for each event of interest were previously constructed by a team of experts and based on 
those, queries were performed in each database of the network, using the corresponding diagnosis 
coding schemes: International Classification of Diseases 9th and 10th revision and International 
Classification of Primary Care, supplemented with additional criteria as laboratory values and 
unstructured free text searches, where applicable. Results were subsequently pooled across all 
databases [25]. The events acute myocardial infarction and upper gastrointestinal bleeding were 
previously validated in the databases concerned [26,27]. 
Method of signal detection 
For EU-ADR, a signal detection method specifically developed for EHR data was used: Longitudinal 
Gamma Poisson Shrinker (LGPS) [28]. LGPS is a cohort-based method, adapted from a Bayesian 
method (DuMouchel’s Gamma Poisson Shrinker, that uses person-time rather than case counts for 
the estimation of the expected number of events. Previous evaluation against other signal detection 
methodologies showed that LGPS is the best performing method in this database system [29]. 
We applied a threshold to the LGPS risk ratio (RR
LGPS
) of a lower limit of the 95% credible interval 
(95%CI)>1 [28]. After LGPS, we applied a second method, Longitudinal Evaluation of Observational 
Profiles of Adverse events Related to Drugs (LEOPARD), which adjusts for possible protopathic bias 
and improves performance. LEOPARD is based on the comparison of rates of drug prescriptions 
initiated within a fixed window (±25 days) prior to and after the occurrence of an event, based on 
the assumption that an increase in the number of prescriptions started after an event relative to 
the number of prescriptions started prior to the event is an indication of protopathic bias. From a 
statistical perspective, this is a binomial test which compares the distributions of prescription before 
and after the event [28]. 
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Verification of signals
We reviewed currently available literature in order to determine which drug-adverse event 
associations identified in the dataset represent already known associations. In contrast to the 
approach used in previous studies, verification was performed for all drug-event associations, 
irrespective of whether a potential signal was flagged or not by any of the signal detection methods 
used in either EudraVigilance or EU-ADR. 
An automatic tool developed within the EU-ADR, which searches MEDLINE-indexed publications 
concerning adverse drug reactions [30,31], was used to qualify the drug-event associations as ‘ADR’ 
(i.e., already known to be true) or ‘non-ADRs’. For each drug-event association MEDLINE citations with 
co-occurrence of the drug and the adverse event of interest were extracted and manually reviewed 
by two independent evaluators with experience in pharmacovigilance and pharmacoepidemiology. 
For the list of ADRs, we considered only those with at least three independent PubMed citations 
that showed a potentially causal association. The lowest level of evidence accepted was 3 case 
reports mentioning the occurrence of a specific adverse event in individual patients exposed to the 
specific drug. The discrepancies in assessment were resolved through discussion. All the associations 
for which not enough evidence was found in the literature (i.e., <3 confirmatory articles) were 
considered ‘non-ADRs’. For these, a random sample of 5% of drug-event associations for each of the 
five events of interest was manually reviewed by the two evaluators. In addition, if at least two drugs 
belonging to the same therapeutic class (defined by common first 5 digits from ATC code) had a 
positive association with a certain event, a class effect was suspected and additional manual review 
of the summary of product characteristics (SmPC) was done to see if other drugs in the class were 
also associated with that specific event. Figure 1 shows a schematic workflow of the verification 
process. 
For purposes of this study, drug-event associations that have been suggested to be ADRs by the 
criteria described above are assumed to be ADRs, otherwise, these associations s are assumed to 
be non-ADRs.
Performance indicators 
In order to assess the complementarity of the systems and to calculate the costs associated with 
identifying potential signals from different sources we used the following indicators:
Percentage of unilaterally identified signals- this is a variation of sensitivity (recall) metrics which uses 
as numerator the number of true associations identified in one system that were not identified in 
the other. We considered this variable useful in quantifying the incremental value of each system.
Sensitivity was calculated as the proportion of associations correctly identified by the method out of 
the total pool of ADRs known to be true from the literature [51]. 
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Figure 1: Workflow of verification of signals 
* A 5% random sample was double-checked by a second reviewer 
† If a class effect is suspected additional manual check is performed and inclusion as an ADR for other class members 
is performed
NND, originally described by Hauben et al. [52] in the context of signal detection within SRS, was 
used as a proxy to express the costs associated with each source of signals. This represents the 
number of signals that would have to be reviewed to detect a single signal that was proven to be 
true. 
Spearman’s correlation coefficient was calculated to determine whether there was a correlation 
between background incidence of the events and each system’s capability to detect signals. 
RESULTS
From an initial dataset of 5,536 drug-event associations overall, 1,490 (27%) potential signals were 
detected in either EudraVigilance or EU-ADR (Figure 2). Upon signal verification, the ratio of ADRs to 
non-ADRs varied from 1:6 for acute pancreatitis to 1:19 for hip fracture.
The therapeutic classes comprising the majority of potential signals identified in EudraVigilance 
were: agents acting on the renin-angiotensin system, antivirals for systemic use and antithrombotic 
agents, while for EU-ADR these were anti-asthmatics, psychoanaleptics and antiepileptics (see 
Figure 2). The percentage of potential signals identified in both systems ranged from 2% to 24%.
The median sensitivity for detecting signals across all events in EudraVigilance was 42% (range 20%–
71%) and for EU-ADR 27% (range 23%–60%), with the values depending on the event of interest 
(see Figure 3). Acute myocardial infarction was the hardest to detect among all five events, with 
65% of known AMI associations from literature not flagged in either database system. Hip fracture 
and bullous eruption seemed to be the easiest to identify overall, with 21% and 28% of known 
associations remaining undetected. From a system perspective, the most easily identified events 
519883-L-sub01-bw-Pacurariu
Processed on: 5-6-2018 PDF page: 48
Chapter 3
48
in SRS were: bullous eruption, acute pancreatitis and upper gastro-intestinal bleeding, while in EHR 
these were: hip fracture, UGIB and AMI.
Figure 2: Distribution of potential signals in EudraVigilance or EU-ADR grouped by ATC therapeutic 
subgroup. 
Note: only classes with >30 potential signals are shown 
The median sensitivity for detecting signals across all events in EudraVigilance was 42% (range 20%–
71%) and for EU-ADR 27% (range 23%–60%), with the values depending on the event of interest 
(see Figure 3). Acute myocardial infarction was the hardest to detect among all five events, with 
65% of known AMI associations from literature not flagged in either database system. Hip fracture 
and bullous eruption seemed to be the easiest to identify overall, with 21% and 28% of known 
associations remaining undetected. From a system perspective, the most easily identified events 
in SRS were: bullous eruption, acute pancreatitis and upper gastro-intestinal bleeding, while in EHR 
these were: hip fracture, UGIB and AMI.
Figure 3: Contribution of each system to signal detection (i.e., % of ‘positive’ associations detected out of 
the total ‘positive associations’ pool in the literature)
n=total number of true associations in the dataset; found in neither= the association was not highlighted as a signal in 
any of the databases during the signal detection process; due to round-up the total sometimes surpasses 100%
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The background incidence of the events, obtained from EU-ADR, was plotted against the percentage 
of unilaterally identified signals. The contribution of each database to signal detection appears to be 
correlated with the background incidence of the events, being positively although non-significantly 
correlated in EU-ADR (R=0.7, p=0.18) and inversely and significantly correlated in EudraVigilance 
(R=-1, p<0.01) (see Figure 4). 
The associated costs were expressed as the number of signals that would need to undergo review 
and further investigation for one true safety issue to be identified. The costs associated with detecting 
signals, expressed by NND, were highly variable across events. With the exception of bullous eruption, 
it seems to be more ‘costly’ to detect safety signals in EU-ADR than in EudraVigilance, with a median 
NND across all events of 7 vs. 5. The most ‘costly’ event in EudraVigilance is bullous eruption 
(NND=8) and the least ‘costly’ are UGIB and acute pancreatitis (NND=2). In EU-ADR, the most costly 
signals to detect are those related to hip fracture (NND=9) and acute myocardial infarction (NND= 7) 
while the least costly are those related to pancreatitis and bullous eruption (NND=3), see Figure 5. 
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Figure 4: Correlation between background incidence of events and contribution of each system to signal 
detection
The background incidences of the events, estimated from EU-ADR data, pooled across all databases are (per 100,000 
person-years): bullous eruption=4.2, pancreatitis=21.4, upper GI bleeding=82.2, hip fractures=117.7, acute myocardial 
infarction=153.7. Identified signals refer to signals proven to be known ADRs; R=Spearman’s correlation coefficient
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Figure 5: Number needed to detect a true association
Note: This represents the ‘cost’ per signal, for example in case of AMI detection in EudraVigilance, 5 signals need to be 
investigated in order to detect one true association.
DISCUSSION 
In this study we aimed to investigate the additional value of EHR for signal detection on top of THE 
traditional spontaneous reporting system. We focused on five different adverse events deemed to 
be important in pharmacovigilance: bullous eruption, acute myocardial infarction, acute pancreatitis, 
hip fracture and upper gastrointestinal bleeding. 
Although EudraVigilance identified more signals overall than EU-ADR, 41% (187/458) signals 
compared to 32% (147/458), as previously shown in other studies [16], this was not unexpected 
considering that EudraVigilance has a worldwide coverage, whereas EU-ADR covered only three 
countries. Furthermore, the EudraVigilance system is primarily designed for signal detection. 
Patadia et al. [16] performed a time-restricted analysis (before and after a safety communication/
media attention) and showed that this impacts the numbers of signals detected in both data sources 
in opposite ways (i.e., increase in number of signals in SRS after media attention and decrease in 
EHR). While this effect might partially explain our findings of higher sensitivity for EudraVigilance, 
we consider it unlikely to entirely explain the difference since the majority of signals tested did not 
attract media attention. 
The capacity of EU-ADR and EudraVigilance to detect signals was shown to differ depending on 
the nature of the adverse event investigated. The relatively poor performance of EudraVigilance in 
detecting hip fractures and AMI might be due to the fact that both events are not usually perceived 
as being drug-induced and thus often fail to be recognized and reported as ADRs, as previously 
hypothesized [34]. The suspected ADRs documented in a SRS like EudraVigilance are highly 
dependent on the reporter’s ability to recognize them as such and some characteristics are helpful in 
this respect: biologic concordance with the drug mechanism of action, short time to onset, positive 
dechallenge, lack of alternative causes. The adverse events which are not so obviously attributed 
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to drugs (as they are multifactorial), or which already have a high background incidence, are likely 
to be poorly captured by spontaneous reports [1,3]. EHR systems do not rely on reporter judgment 
therefore these events may be better represented in such systems. 
On the other hand, there is a very low sensitivity for detecting rare drug-induced events in EU-ADR 
and this is in line with previous research which showed that, despite the broad coverage of the EU-
ADR network (around 20 million of patients) there is simply not enough (statistical) power to identify 
very rare events in the database [24]. Thus, for rare events that have drug treatment as primary 
etiology, SRS still seems to be the better solution so far. Our findings are consistent with those of 
Patadia et al., [34] although different parameters were used to determine the complementarity of 
the two systems. 
We found a correlation between the background incidence of the events and the contribution of 
each database to signal detection; the correlation was statistically significant for EudraVigilance, but 
not for EU-ADR, which may be due to the low number of events tested. 
The burden associated with screening any data source for signals depends on the number of 
signals that require further assessment or investigation and the workload involved in each of 
these investigations. The amount of work needed to confirm or refute a signal is highly variable, 
ranging from simple product information checks to performing more complex analyses and formal 
pharmacoepidemiologic studies. Pizzoglio et al. reported in their study a median time of 6 hours 
for initial assessment of a signal (range 2–26 hours) [35]. We did not collect similar information on 
time spent on assessment of the signals in our study since a semi-automatic method was used; 
however, we considered the number of signals which need further investigation to be a reasonable 
proxy to express the associated costs. We found that for all the events (with the exception of bullous 
eruption), it is more costly to identify signals within an EHR-based system. However there is a notable 
difference across events as follows: for hip fracture, where EU-ADR provided the most added value, 
80% increase in cost per signal was observed compared to detection in EudraVigilance. On the other 
hand, for acute pancreatitis, the cost associated with signal detection in EU-ADR was not much 
higher compared to that in EudraVigilance; therefore, in this case it may be justifiable to use both 
systems. Because the two systems provided roughly the same contribution to detection of UGIB-
related signals, the value of supplementing SRS with EHR-based systems is probably dependent on 
the types of drugs that can be captured in the particular EHR database. Detecting acute myocardial 
infarction proved to be costly in both systems; however, the seriousness of the event, its public 
health impact and the difficulty in detection might justify the extra cost of using both SRS and EHR. 
For bullous eruption, due to lack of additional gain (only one extra signal identified), it might not be 
efficient to use EHR as a secondary signal source. 
The range of events tested in this study, albeit carefully selected, represents only a small sample of 
all possible adverse events and therefore limits the external validity of this research. Applicability of 
our findings to a broader range of events will require further investigation. In addition, the overall 
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background incidence of the events selected is slightly skewed towards more common events and, 
if our hypothesis holds true, this might have resulted in a bias favoring EHR performance. 
Another limitation was the retrospective nature of the study: we actually tested the capacity of 
systems not to identify signals but rather already identified safety issues. As Noren et al. pointed 
out, ideally, the evaluation should be made using emerging safety issues and not well-established 
ADRs [36]. This is a common limitation in signal detection research, however, due to the difficulties 
that accompany building a ‘reference standard’ and long time needed to gather data prospectively. 
Moreover, combining the two systems involved many decisions regarding the choice of signal 
detection method and their implementation (e.g., choice of thresholds and precision estimates) 
which have a LARGE impact on the results [37]. In addition, it was repeatedly demonstrated that the 
aggregation level at which data mining is performed influences the results [38,39] and we consider 
THAT the appropriate level is still an open question. The decision to use SMQs instead of preferred 
terms (PTs) might have an impact on the results. We acknowledge that use of different signal 
detection methodologies and reference standards as well as the definition of events used in data 
mining may lead to different results. Therefore, our results may reflect to some extent the relative 
strengths of each data source but they will also be influenced by the algorithms chosen. Although 
we acknowledge that time to signal detection is an important element to take into account, for this 
study we focused primarily on other quantitative measures such as number of signals and number 
of false positives which are equally important. 
This evaluation did not take into account the fact that an EHR-based surveillance system would 
require additional work for implementation and subsequent maintenance for the purposes of signal 
detection (vs. SRS which are already established for such activities) and would thus incur extra costs 
which are difficult to estimate. 
Our study is one of the few performed studies so far which tried to explore how a SRS and an 
EHR-based system might be used together with the aim of augmenting drug safety surveillance. 
A previous study by Harpaz et al. [12] had a similar aim but a different strategy, trying to combine 
information from both data sources at a very early stage in order to improve the ranking of signals 
by replication of findings. In contrast, we explored the scenarios where use of EHRs can fill the gaps 
and provide added value to the already existing systems.
519883-L-sub01-bw-Pacurariu
Processed on: 5-6-2018 PDF page: 53
Electronic healthcare records for signal generation and validation - two possible uses
53
3
CONCLUSION
The more prudent goal in signal detection is the identification of not all but the majority of signals 
in the most efficient way – with the least time and resource-consuming approach. With this aim in 
mind, we showed that EHR may complement SRS in certain situations, especially in the presence 
of adverse events with high background incidence. While SRS appeared to be more cost-effective 
overall, for some events which are very hard to pick up, the costs associated with additional signal 
detection in an EHR-based system may be justifiable. 
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ABSTRACT 
Background and Objectives: Ischemic colitis is the most common form of intestinal ischemia. In 
addition to other aetiologies, Ischemic colitis can also be caused by drugs such as alosetron and 
cocaine. An association between the use of triptans and Ischemic colitis has been hypothesised but 
not yet proven. The objective of this study was to estimate the risk of ischemic colitis during triptans’ 
use in a migraine cohort. 
Methods: This is a population based case control study using an UK primary care database. Incident 
ischemic colitis cases ≥ 18 years of age were matched to controls within the same migraine cohort. 
Drug use was assessed in the last 24 months before event and odds ratios were calculated by 
conditional logistic regression, adjusting for known confounders from literature. 
Results: Within the migraine cohort of 293,037 patients, we identified 41 incident cases of ischemic 
colitis. Use of triptans in the previous 12 months increased the risk of ischemic colitis compared to 
no use (OR=2.29, 95%CI 1.02–5.15). When we split the exposure window in current and past use, 
the results became non-significant; the risk was highest for the past use category (use 3–12 months 
before event) (OR=2.57, 95%CI 0.88–7.54). After 12 months, the risk decreased to (OR=1.90, 95% 
0.44–8.13). 
Conclusions: We observed that triptan use 12 month before the event in a cohort of migraine 
patients, increases the risk of ischemic colitis. The highest risk appears to occur in the period 12 to 3 
months prior to event. Considering the wide confidence interval and the limited number of cases 
included we were not able to further explore the risk windows. We consider that this finding should 
not be considered definitive and should be replicated in a more powered study.
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INTRODUCTION 
Triptans are selective serotoninergic receptor (5-HT
1B/1D
) agonists that have been approved since 1991 
for acute treatment of migraine [1]. Although triptans are rather selective for the vascular receptors 
in the nervous system, they may also cause vascular constriction outside the cerebral vascular 
bed [2]. Triptans have been reported to induce myocardial ischemia and stroke, albeit in very rare 
instances [3,4]. In addition, it has been suggested that triptans might also cause vasoconstriction in 
the splanchnic circulation, since the gastrointestinal cavity is known to have a strong serotoninergic 
signalling [5]. A few anecdotal reports of ischemic colitis (IC) following use of triptans have been 
reported [6-8]. All triptans’ package inserts mention that colonic ischemia with abdominal pain and 
bloody diarrhoea has been reported in the post-marketing setting. 
IC is the most common form of intestinal ischemia. It usually results from an interruption of colonic 
blood flow due to low flow states or thromboembolic events [9]. Classic symptoms include lower 
abdominal pain, diarrhoea and rectal bleeding in patients without a history of inflammatory bowel 
disorders. The estimated incidence of IC ranges from 4.5 to 44 cases per 100,000 person-years, 
depending on underlying comorbidities [10,11] and abruptly increases with age. IC is a serious 
condition, that may lead to bowel infarction, necrosis and may even be fatal [12]. The most common risk
factors are severe hypotension, hypercoagulable states, mechanical bowel obstruction, abdominal 
surgery, inflammatory bowel disease, ischaemic heart diseases, cancer and severe constipation [11-
13]. Some medications may also cause IC through vasospasm or vasoconstriction, thrombogenesis 
or through shunting of blood from mesenteric vessels [14]. For several drugs a possible association 
with IC was established, for example alosetron, cocaine, ergotamine, opioids, estrogens, taxanes and 
vinca alkaloids [14,15]. Alosetron, a 5-HT3 antagonist used for the management of irritable bowel 
syndrome was even withdrawn from the market for this reason [16]. 
To our knowledge, the association between triptans and IC was investigated only in two studies 
so far: a case series [6] of seven patients and a case-control study in a USA claims database [15]. 
The case series has suggested a possible association between triptans and IC and recommended 
further investigation. The case control study did not find an association, however it included only a 
very small group of triptans users (16 triptan users out of which 2 IC cases) and only hospital cases. 
OBJECTIVE
Given the lack of good quantitative data from general practice, the aim of this study was to assess 
the risk of IC associated with use of triptans in migraine patients. 
519883-L-sub01-bw-Pacurariu
Processed on: 5-6-2018 PDF page: 60
Chapter 3
60
METHODS
Data source
We used The Health Improvement Network (THIN) as data source. THIN is a population-based 
electronic health care records database with data from 562 general practices all over the United 
Kingdom [17,18]. In the UK, all patients are registered to a general practitioner, who acts as a 
gatekeeper for secondary care. THIN reflects UK general population and comprise diagnostics from 
general practitioners, as well as discharge letters, prescriptions outside hospital and some lifestyle 
related information. It has been demonstrated that the clinical information in THIN is sufficiently 
accurate for use in epidemiological studies [18]. Investigators had access to the full version of THIN 
database when creating the study population. The study was approved by IMS Health Committee 
(SRC Number: 16THIN083). 
Design, study population and follow-up 
We conducted a case-control study nested in a cohort of patients that were diagnosed with 
migraine. The migraine cohort consisted of all patients aged ≥18 years who had at least one year of 
valid data in the database (run-in period) and at least one record of migraine or cluster headache 
diagnosis. The study period started from 1st January 2003 and ended 31st December 2015. Patients 
entered the migraine cohort upon the latest of the following dates: start of study period, fulfilling 
one year of database history, reaching 18 years of age or a diagnosis of migraine. The run-in period 
was used to check the patient’s medical history and to distinguish between incident and prevalent 
cases of IC. Follow-up ended upon end of study period, transfer out of the practice or diagnosis of 
IC, whichever date was the earliest.
Cases and controls 
The outcome in this study was incident ischemic colitis, which was identified by READ codes. 
The date of the first recorded IC diagnosis date was used as the index date. Controls were cohort 
members without a diagnosis of IC prior or at the index date of the case. For each case, a maximum 
number of 100 controls were drawn from the cohort using the incidence density sampling method 
[19]. Controls were matched to cases on age (±1 year) and sex. The following exclusion criteria were 
applied to both cases and controls: 
• subjects with a diagnosis of colorectal cancer or inflammatory bowel disease prior to the index 
date,
• prevalent cases of IC (first diagnosis before cohort entry), 
• prevalent users of triptans (first prescription issued before cohort entry),
• one of the following acute conditions recorded within 3 months prior to the index date: acute 
pancreatitis, sepsis, cardiovascular or hemorrhagic shock, abdominal or aortic surgery, infectious 
colitis and acute deep vein thrombosis. 
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Drug exposure
Exposure to triptans was assessed based on prescription drug codes. Cases and controls were 
classified as triptan users or non-users in the mutually exclusive exposure categories to investigate 
the hazard shape: 
• Current use: any prescription received 3 months before the index date 
• Past use: any prescription received > 3 months and <=12 months before the index date 
• Distant past use: any prescription received >12 and <=24 months before the index date
• No use (reference): no prescription received in the last 24 months (see Figure 1). 
In order to increase the power we aggregated current and past use in one category. 
Covariates
The following covariates were considered as risk factors for IC: smoking status (categorised as current 
smoker, non-smoker and smoking unknown), constipation, hypertension, diabetes type II, ischemic 
cardiovascular disease, atrial fibrillation, pulmonary embolism, deep vein thrombosis, treatment 
with opioids, oestrogens or ergotamine [11,12,20]. If one of the diagnoses was recorded within one 
year before the index date, the patient was classified as having the disease. Study subjects were 
classified as exposed to drugs if prescriptions were recorded in the one year prior to the index date. 
All covariates were identified through structured diagnostic and drug codes.
Statistical analysis
The incidence rate of IC in the migraine cohort was calculated by dividing the number of incident 
cases by the total number of person-years at risk. 
The differences of various characteristics between cases and controls were determined by ANOVA 
for continuous variables and by chi-square or Fisher’s exact test for categorical variables.
To estimate the relation between triptan prescriptions and the risk of IC, we estimated the odds ratios 
using conditional logistic regression. Identification of confounders was performed by a backward 
selection procedure; confounders were kept in the model if the risk estimate for drug exposure 
changed more than 10% or if they improved the fit of the model significantly [21]. All analyses were 
performed using SAS version 9.4.
We conducted a sensitivity analyses extended definition of IC in an attempt to capture more cases 
and to check the robustness of our estimates. 
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RESULTS
The initial migraine cohort consisted of 293,037 patients, with a mean age at entry in the cohort of 
43.6 years (IQR range 31–54), and 74.3% females (see Table 1). The cohort had a median follow-up 
of 6.7 years≤ (range: 2.8–10.9 years). Within this cohort, we identified 42 incident cases of IC, which 
led to an overall incidence rate for IC of 2.3/100,000 person-years. More than 70% of cases occured 
in the >60 years age category. The percentage of triptan users in the migraine cohort was 32% 
(94,256 users). Among triptan users, sumatriptan was the most commonly used (62%), followed by 
rizatriptan (14%) and zolmitriptan (10%).
After exclusion of patients with comorbidities, and exclusion of prevalent triptan users, the remaining 
41 cases were matched to 4,005 controls (see Figure 1). 
Initial migraine cohort
n=293,037
Colon cancer
n=16
IBD
n=170
Prevalent user 
of triptans*
n=31,048
Ischemic colitis
n=4
261,799 patients
Acute conditions**
n=1
Cases
n=41
Controls
n=4,005
Figure 1: Flowchart for patient’s recruitment
* Patients with at least one triptan prescription issued during run-in period; ** Patients with at least one of the following 
acute conditions recorded in the past 3 months prior to the date of IC for cases or matched index date for the controls: 
acute pancreatitis, sepsis, cardiovascular or hemorrhagic shock, abdominal or aortic surgery, infectious colitis and acute 
deep vein thrombosis; IBD=irritable bowel syndrome 
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Table 1: Characteristics of the initial migraine cohort 
Variable n=293,037 
Gender (Female, (%))  74.3%
Age (years) (mean, IQR range) 43.6 (31–54)
≤40 years 45.3%
>40 and <60 years 37.7%
≥60 years 16.9%
The main characteristics of cases and matched controls at index date are presented in Table 2. Being 
a current smoker increased the risk of ischemic colitis (OR=2.67 (95%CI 1.07–6.67)), as well as being 
treated with opioids (OR=3.17 (95%CI 1.60–6.28)). The number of patients treated with ergotamine 
was very low (less than 5 patients) therefore this variable was not further considered in the analysis. 
Table 2: Characteristics of cases and matched controls at index date
Cases Controls p-value*
(n=41) (n=4,005)
Gender (Female, (%)) 33 (80.49) 3,205 (80.02) 0.941
Age (years) (median, range) 59 (32–95) 59 (31–96) 0.693
BMI (mean ± sd) 26.34±7.33 26.52±5.62 0.836
Smoking status 0.459
 Current smoker 9 (21.95) 432 (10.79)
 Non-smoker 12 (29.27) 1,500 (37.45)
 Unknown 20 (48.78) 2,071 (51.71)
Co-morbidities (n, (%))
 Constipation 13 (31.71) 828 (20.67) 0.083
 Hypertension 3 (7.32) 188 (4.69) 0.442
 Diabetes type II 2 (4.88) 376 (9.39) 0.427
 Ischemic cardiovascular disease 4 (9.76) 201 (5.02) 0.152
 Atrial fibrillation 6 (14.63) 286 (7.14) 0.117
 Deep vein thrombosis 0 (0) 82 (2.05) 1.000
Triptans use 0.078
Current use 4 (9.75) 241 (6.01)
Past use 4 (9.75) 166 (4.14)
Distant past use 2 (4.87) 128 (3.2)
Co-medication use (n, (%))
 Oestrogens 12 (29.27) 923 (23.05) 0.347
 Opioids 27 (65.85) 1623 (40.52) 0.001
Duration of follow up in days (median, range) 2,352 (33–4,724) 3,073 (12–4,724) 0.284
*p-values for differences between cases and controls determined by ANOVA and chi-square test or Fisher exact test for 
categorical covariates where appropriate; ** Bold font indicates significant differences; BMI=Body Mass Index 
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In the unadjusted analysis, the risk of IC was not increased with current use of triptans (OR=1.97 (95% 
CI 0.68-5.76)), past use (OR=2.86 (95%CI 0.98–8.31)) or distant past use categories (OR=1.85 (95%CI 
0.43–7.87)). Aggregation of current and past use resulted in an OR of 2.42 (95%CI 1.08–5.38).
Adjustment for the selected confounders (smoking status, opioid use and body mass index (BMI)) 
led to a small decrease in risks for all exposure categories (see Table 3). Aggregation of current 
and past use resulted in an OR of 2.29 (95%CI 1.02.–5.15). If we used a broader definition of IC, the 
unadjusted estimate dectreased to 1.74 (95%CI 0.77–3.89). 
Table 3: Risk of IC with use of triptans 
Triptans exposure Number of cases/
controls
OR (95%CI) OR adj* (95%CI)
No use 31/3470 Reference Reference 
Current+past use 8/407 2.42 (1.08.–5.38) 2.29 (1.02.–5.15)
 Current use <3 months 4/241 1.97 (0.68–5.76) 1.94 (0.66–5.72)
 Past use (>3 and <=12 months) 4/166 2.86 (0.98–8.31) 2.57 (0.88–7.54) 
 Distant past use (>12 and <=24 months) 2/128 1.85 (0.43–7.87) 1.90 (0.44–8.13)
*adjusted for smoking status, opioid use and BMI
DISCUSSION
In this case control study nested in a cohort of migraine patients we have observed that triptans’ 
use in the previous year increases the risk of IC. The data suggest that the risk is higher within 3 to 
12 months prior to diagnosis, decreasing for more distant exposures. The results were borderline 
significant.
Strengths of the current study include the population based setting, ensures the allows for 
identification of all potential IC cases in the population. The controls were derived from the same 
source population. By nesting our study in a migraine cohort and matching we reduced the potential 
(un)measurable confounding by indication. 
To our knowledge this is the second study that has evaluated this association and the first one 
conducted in an European database. The previous case control study was performed in an US 
claims database (Kaiser Permanente Medical Care Plan) [13], and did not find an association (the 
exact estimate was not provided). However this study was not focused specifically on triptans as the 
authors investigated a wide range of diseases and drugs associated with IC. They also had limited 
power due to a low number of cases (16 triptans’ users out of which 2 cases). 
Our study also has several limitations. Firstly, the lack of power due to limited number of cases, 
which restricted us to further investigate exposure windows. As in any observational study, the 
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other limitations can be classified in: misclassification of outcome, misclassification of exposure and 
confounding.
Misclassification of outcome
The incidence of IC in the literature is 4.5 to 44 cases per 100,000 person-years and varies almost 
100 fold with age, with one study reporting annual incidence rates ranging from 1.1 per 100,000 
among those under age 40 years to 107 per 100,000 among those aged 80 years or older [11]. Our 
calculated incidence was lower than the estimates from the literature; (2.3 per 100,000 person-years) 
and this might be due to several reasons. The most logical reason is age, the migraine cohort is 
younger than the populations from other studies which investigated IC; whereas we have a mean 
age of 46.3, other studies have a mean age of 71.6 [11] or 69 years [15]. Secondly, IC is a diagnosis 
with unspecific symptoms (abdominal pain, diarrhea and rectal bleeding) and no specific diagnostic 
test, therefore it can be under-diagnosed by specialists. This is more likely for chronic IC, since acute 
IC is life-threatening and therefore much less likely to be underdiagnosed. Thirdly, to guard against 
case misclassification, we used a rather strict definition of IC and we might have missed some cases. 
However, we performed a sensitivity analysis with a broader diagnosis definition in an attempt 
to capture more cases. This led to a decrease in the estimate, suggesting that, if the association 
between triptans and ischemic colitis is real, the extended definition included false positive cases 
and should not be used. We did not validate the cases by chart review and we are not aware of any 
study which used a validated definition of IC. 
Misclassification of exposure
It is known that the choice of the exposure risk window has a big impact on the risk estimate since 
risks vary over time. To account for prevalent users’ bias, we excluded prevalent triptan users at 
cohort entry. We did not have any indication from literature about the exposure risk window for 
triptans and IC, therefore we used multiple risk windows. We assumed that an effect of triptans on 
gastrointestinal vasculature would have an acute or medium latency time (similar to the effects on 
other vasculature). However prescription records are inadequate to estimate accurately the actual 
timing of use since this class of drugs is used as needed, therefore we assumed there could be 
quite a lag time between prescription time and time of actual intake. In this case, misclassification 
of exposure is very likely, though non-differential between groups. To address this we investigated 
multiple risk windows: current, past and distant past use and then aggregated across the categories 
with similar risks. 
Confounding 
The potential confounders were identified from literature and other studies on ischemic colitis and 
they are quite diverse, including comorbidities, concomitant drugs and lifestyle-related factors such 
as smoking. With regards to the concomitant drugs, we decided not to adjust for NSAIDs since 
the evidence of them being a risk factor is weak and most NSAIDs are also prescribed over the 
counter and are therefore not captured in the database, so we would adjust for a highly misclassified 
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confounder [14]. We did adjust for smoking which is a known risk factor for the outcome, however 
we also know that smoking is misclassified in THIN, leaving some residual confounding.
In spite of potential misclassification of exposure, the finding of a significant increased risk of ischemic 
colitis following use of triptans would warrant further studies. Considering the wide confidence 
interval and the limited number of cases that we were able to include we consider that this finding 
should not be considered definitive and should be replicated and studied in a more powered study. 
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ABSTRACT
Background and Objectives: Spontaneous reports of suspected adverse drug reactions (ADRs) can 
be analysed to yield additional drug safety evidence for the pediatric population. Signal detection 
algorithms (SDAs) are required however the performance of SDAs in the pediatric population 
specifically is unknown. 
Methods: We tested the performance of two established SDAs: Proportional Reporting Ratio (PRR) 
and Empirical Bayes Geometric Mean (EBGM) on a pediatric dataset from USA. We compared SDAs’ 
performance to a published pediatric-specific reference set, by calculating diagnostic-test related 
statistics as the area under the Receiver Operating Characteristics curve (AUC). The impact of age 
stratification and age-adjustment SDAs’ performance was assessed. Age adjustment was performed 
by pooling (Mantel-Hanszel) stratum-specific estimates. 
Results: A total of 115,674 pediatric reports (patients aged 0–18 years) comprising 893,587 drug-
event combinations were analysed. Crude values of the AUC were similar for both SDAs: 0.731 (PRR) 
and 0.745 (EBGM). Stratification unmasked four DECs, for example ‘ibuprofen and thrombocytopenia’, 
which prove to be real signals. Age-adjustment did not improve performance. 
Conclusion: The performance of the two tested SDAs was similar in the pediatric population. Age 
adjustment does not improve performance and is therefore not recommended to be performed 
routinely. Stratification can reveal new associations, therefore is recommended when either drug 
use is age-specific or when an age-specific risk is suspected. 
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INTRODUCTION 
Spontaneous reports of suspected adverse drug reactions (ADRs) can yield important information 
regarding the safety of drugs [1]. Usually, such reports are screened for emerging safety issues by 
applying statistical methods called signal detection algorithms (SDAs). Current SDAs compare the 
reporting rate of a drug-event combination (DEC) of interest with the expected count calculated from 
the overall reporting rate of that reaction in the entire database [1,2]. Although SDAs are routinely 
applied to reports pertaining to the general population, the performance of SDAs in the pediatric 
population specifically has not been investigated to date. Compared to adults, the pattern of drug 
use and occurrence of ADRs in pediatrics may differ [3-5] since the latter population comprises a 
heterogeneous group of subjects at various stages of development with age-dependent organ 
maturation and hormonal changes [6]. Several studies investigating ADR reporting in children 
identified different reporting patterns in this population compared to adults [3,5,7,8]. Since ADRs 
may be age-specific, adjustment for age seems to be a logical step when investigating pediatric 
ADRs and has been advocated by some researchers [4]. The major aim of stratification is verification 
of confounding and effect modification which otherwise may mask true signals [9]. Confounding 
by age can be dealt with by stratifying for age categories and pooling stratum-specific estimates. 
However if age specific estimates differ (in case of effect modification) pooling/adjustment should 
not be done, but instead, a verification of each individual stratum. While stratification has been 
investigated by some researchers [10], adjustment is routinely implemented in some Bayesian 
but not in frequentist SDAs [11-13]. Few studies have systematically addressed the impact of age 
stratification or adjustment and the results are contradictory [9,14,15].
Within the context of the Global Research in Pediatrics (GRiP) Network of excellence [16], we aimed to 
evaluate the performance of two well-established SDAs in the pediatric population and determine if 
age stratification or adjustment impacts signal detection in this population. 
METHODS
Data source
Data was retrieved from the publicly available version of the US FDA Adverse Event Reporting System 
(FAERS), which comprises spontaneous reports of suspected ADRs submitted by manufacturers, 
healthcare professionals and patients. FAERS is one of the largest repositories of spontaneous reports 
in the world [17,18]. In this study, we analyzed reports received from the first quarter of 2004 through 
the third quarter of 2012. 
For performance analysis, only reports of ADRs occurring in children and adolescents (<18 years of 
age) were retained. The ADRs in FAERS are coded according to the Medical Dictionary for Regulatory 
Activities (MedDRA®) [19]. 
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To improve the quality of the dataset, we excluded reports with missing age, the main variable in our 
study. Also, reports with reported age equal to zero and with a MedDRA® preferred term indicating 
prenatal exposure were removed, as these imply in-utero drug exposure and were therefore not 
relevant for our study. We minimised the number of duplicates (i.e. the same report submitted by 
different reporters) by applying an algorithm based on case identifier, report identifier, drug and 
event names. For multiple reports (i.e. the same report is reported at a later time, with additional 
and updated information) [20], the most recent (and most updated) report was retained for analysis.
As drug names included in FAERS are not standardized, a harmonization procedure was implemented. 
Briefly, this consisted of removing superfluous characters and applying a generalized edit distance 
matching algorithm [21] to map free text drug names to synonyms and finally to the corresponding 
active substance and World Health Organization-Anatomic Therapeutic Chemical (WHO-ATC) code. 
In this study, only those drugs reported as primary or secondary suspect in the FAERS database were 
retained for analysis. Analysis was performed at Drug-Event Combination (DEC) level, meaning that 
within each report, every suspect drug was combined with all reported ADRs. Thus, one report may 
comprise more than one DEC. 
Signal detection algorithms (SDAs)
We tested two well established SDAs which are routinely used by various national and international 
regulatory and/or research institutions for signal detection: the proportional reporting ratio (PRR) [2]
and the empirical Bayes geometric mean (EBGM) [13] (see Table 1). We also tested count of reports, as 
a positive control. In order to define a signal of disproportionate reporting (SDR) [22,23], we selected 
thresholds that are currently applied in routine practice. We applied the SDAs at the end of the study 
period, when the maximum number of reports had accrued. 
Table 1: Signal detection algorithms and corresponding thresholds applied
Signal Detection 
Algorithm 
Applied Thresholda Institution where the method is 
currently used 
Number of reports n≥5 NA
PRR PRR lower bound 95%CI≥1 & n≥5 reports European Medicines Agency 
EBGM EB05 CI≥1.8 and n≥3 reports & EBGM ≥2.5 Medicines and Healthcare products 
Regulatory Agency (MHRA)
PRR=Proportional reporting ratio; EBGM=Empirical Bayes Geometric Mean; CI=confidence interval; NA=Not available; 
EB05=Lower bound of the 95% confidence interval; a Thresholds were obtained from Candore et al. [23]
Performance assessment measures
The performance of the SDAs was assessed by calculating diagnostic-test related statistics, namely 
specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) [24,25]. 
Sensitivity is the ability of the method to correctly identify true signals while specificity is the ability 
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to correctly exclude false signals. PPV and NPV are posterior probabilities, describing how many of 
the signals classified as positive or negative are correctly classified [24,25]. 
Since diagnostic-test related statistics are dependent on the threshold choice, their individual 
comparison has only limited, albeit practical value. Therefore, we also estimated the area under the 
curve (AUC) of receiver operating characteristics in order to compare the performance of the SDAs 
[32]; the AUC incorporates both sensitivity and specificity across all the possible values for a certain 
SDA. Calculation of AUCs was conducted by varying only the point estimate of each SDA and did not 
take into account the other components of the SDA.
For the purpose of performance evaluation, a previously constructed pediatric-specific reference 
set of positive and negative drug-event associations was used [26]. It consists of 37 positive and 90 
negative DECs and includes drugs that are administered to children and events that are regarded as 
important for this population. The positive DECs are those that were confirmed to occur based on 
evidence from product information and the published literature, while the negative DECs are those 
that could not be confirmed at the time of literature review by neither the SmPC nor the published 
literature. For a full description of the reference set, see Osokogu et al. [26].
Stratification and adjustment for age
The impact of age stratification and adjustment on the performance of the SDAs was investigated. 
First, we checked for possible effect modification across age strata, by stratifying the data according 
to age categories defined according to International Conference on Harmonization (ICH) [27] and 
calculating stratum-specific measures for each SDA. 
Secondly, we calculated age-adjusted estimates for PRR and EBGM by combining the stratum-
specific estimates in an overall measure [28]. The performance of each SDA was reassessed after age 
adjustment. 
Statistical analysis
Differences in the performance (AUC) of each SDA, crude versus age-adjusted and crude versus 
count of reports (positive control) were tested using paired chi-squared tests. Stratum-specific 
contingency tables were tested for homogeneity using the Breslow Day Tarone test [29]. The 
Mantel-Haenszel approach was used for pooling and calculating age-adjusted estimates [28]. The 
lower bound of the EBGM 95% confidence interval (EBGM05) was calculated using the EB05 for 
each stratum and then computing a Mantel-Haenszel average based upon Zeinoun [30]. Statistical 
significance was defined by p value <0.05. 
Analysis was performed using SAS software version 9.2. Graphs were made in SAS software version 
9.2 and R version 3.1.3. 
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RESULTS
Descriptive analysis 
For the study period (first quarter of 2004 through the third quarter of 2012), a total of 4,285,088 
reports were retrieved from FAERS. After eliminating duplicates (n=43,125), removal of adult reports 
(n=2,686,530) and reports with missing age (n=1,419,524) or reports indicating prenatal exposure 
(n=20,235), 115,674 reports corresponding to 893,587 individual DECs were retained for analysis of 
pediatric spontaneous reports (see Table 2). 
Table 2: Description of pediatric reports by age categories
Age group Number of reports, n (%)
Neonates: 0–27 days 5,091 (4.40%)
Infants: 28 days–23 months 12,566 (10.86%)
Children: 2–11 years 49,982 (43.21%)
Adolescents: 12–17 years 48,035 (41.53 %)
Total 115,674 (100%)
The total number of pediatric reports that included the investigated drugs and ADRs from the 
reference set can be observed in Figure 1, which also shows data regarding adults (for comparison 
purposes). The number of children exposed to the drugs of interest, for which any of the investigated 
ADRs was reported, varied from 26 patients (for praziquantel) to 7,535 patients (for ibuprofen) with a 
median of 781 patients exposed across all drugs. The number of events of interest in FAERS ranged 
from 164 reports (ventricular arrhythmia) to 14,777 (anaphylaxis), with a median of 1,004 reports 
across all events. 
Overall performance of SDAs 
Both SDAs showed high specificity and low sensitivity. They both had similar specificity values (PRR: 
83.8% and EBGM: 91.9%), while sensitivity was lower for EBGM than for PRR (17.2% vs. 37.9%). The 
NPV and PPV were similar for both SDAs. When we applied the threshold-independent (AUC-based) 
approach, the tested SDAs showed similar performance in the pediatric population although the 
AUC value for EBGM (0.745) was slightly higher than for PRR (0.731). None of the SDAs performed 
better than the simple report count (AUC=0.634, p-values: PRR=0.27 and EBGM=0.14)
Stratification and adjustment for age and its impact on performance 
Upon calculating SDA values per age stratum and testing for heterogeneity across strata, we 
observed effect modification for some associations. Some false negatives (positive DECs which 
failed to be highlighted as signals when analysing data pertaining to the entire pediatric population) 
were unmasked in some strata. Four DECs were unmasked: ibuprofen-thrombocytopenia and 
isoniazid-seizure (by PRR) and clarithromycin-erythema multiforme and ibuprofen-erythema 
multiforme (by EBGM). Conversely, ‘ibuprofen-acute liver injury’, also a positive DEC, was highlighted 
when we analyzed data pertaining to the entire pediatric population but after stratifying, it became 
clear that this DEC was highlighted  only in older children (adolescents), and not highlighted 
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Figure 1: Count of reports in pediatric and adult population for the investigated ADRs and drugs, 
cumulatively for the period Q1 2004–Q3 2012a
a Number of reports in children is represented by bars and plotted on the left axis, while the number of reports in adults is 
represented by the red line and plotted on the right axis; Reports with missing age or age=0 were excluded. Only reports 
mentioning any of the drugs or events in the reference set were considered. 
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in younger children (see Figure 3). For an overview of SDA values across age strata and results of 
heterogeneity tests please refer to the Electronic Supplementary material Figures 1A and 1B. 
Figure 2: Performance of signal detection algorithms within the entire pediatric population 
SDA Sensitivity Specificity PPV NPV AUC p-valueb
Number of reports 58.62 67.57 58.62 67.57 0.634 reference
PRR 37.93 83.78 64.71 63.27 0.731 0.266
EBGM 17.24 91.89 62.50 58.62 0.745 0.144
After age adjustment a (reference-crude PRR/EBGM)
PRR 34.48 86.49 66.67 62.75 0.688 0.267
EBGM 10.34 97.30 75.00 58.06 0.683 0.216
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1 –Specicity
EBGM PRR
SDA EBGM EBGM adjusted Number of Reports PRR PRR adjusted
SDA-signal detection algorithm; PRR= Proportional reporting ratio; EBGM= Empirical Bayes Geometric Mean; AUC=area 
under the curve; PPV=positive predictive value; NPV-negative predictive value. a adjusted PRR/ROR values calculated 
by combining the individual estimates from each age stratum into one measure according to the Mantel-Haenszel 
approach. b paired chi-square test 
We evaluated the performance of the methods within individual age strata (see Table 3). On average, 
performance of the SDAs was lower within age strata compared to the entire pediatric population 
and performance improved with increasing stratum size. For infants and neonates, the performance 
was very low, not better than chance (p-value>0.5 for both SDAs). The adolescent group exhibited 
the best performance, which was similar to the overall performance. 
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Figure 3: Variation of PRR and EBGM estimates across pediatric specific strata – selected examples
p-values were calculated with Breslow Day Tarone test for homogeneity
Table 3: Performance of signal detection algorithms across age strata
Age groups
(number of reports)
Signal detection algorithms AUC
Neonates (5,091) Number of Reports 0.625
EBGM 0.600
PRR 0.65
Infants (12,566) Number of Reports 0.667
EBGM 0.548
PRR 0.554
Children (49,982) Number of Reports 0.654
EBGM 0.698
PRR 0.649
Adolescents (48,035) Number of Reports 0.698
EBGM 0.771
PRR 0.718
Entire pediatric population (115,674) Number of Reports 0.634
EBGM 0.745
PRR 0.731
PRR= Proportional reporting ratio; EBGM= Empirical Bayes Geometric Mean; AUC=area under the curve 
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After adjusting for age by pooling the stratum-specific estimates, the performance of the SDAs 
decreased, although not significantly (see Figure. 2; crude vs. adjusted AUC for PRR 0.731 vs. 0.688, 
p-value=0.267; crude vs. adjusted AUC for EBGM 0.745 vs. 0.683, p-value=0.216). 
DISCUSSION 
In this study, we have demonstrated that age stratification for detection of drug safety signals 
in children may unmask some signals that do not appear in neither crude nor adjusted analysis. 
Adjustment for age does not improve performance of the PRR or EBGM. 
For the investigated events, similar reporting patterns were observed for children and adults while 
the investigated drugs appeared to have different reporting patterns (see Figure 1). Different drug-
related reporting patterns in children vs adults were previously reported [5]. Consequently, reported 
DECs for children may differ from adults, [3,5] underlining the need for pediatric-specific approaches 
to signal detection especially when we consider that even within the pediatric population, reported 
drugs may vary by age group [3,31]. 
Overall, the PRR and EBGM showed good performance although results were slightly lower than 
results reported on other (not pediatric-specific) reference sets [32,33]. The similarity in performance 
between PRR and EBGM is in accordance with the recent results from the PROTECT project [23]. 
The fact that the performance (based on AUC) of PRR and EBGM was not statistically significantly 
better than simple report count may be due to the lack of power. Within age strata, performance 
seemed to correlate with stratum size: the poorest results were observed for infants and neonates 
(the smaller groups), slightly improving for children while the best performance was observed for 
adolescents, the age stratum with the highest number of tested DECs. Decrease in power due to 
fewer reports and therefore DECs may account for this observation. The fact that we used lower 
bounds of confidence intervals for signaling instead of point estimates might have exacerbated the 
influence of sample size on the results, since smaller strata will have higher variability. In neonates 
and infants for whom expected counts were difficult to calculate because of few reports, we 
observed that simple report counts performed similar or even better than the SDAs and might be 
an alternative to commonly used SDAs. The fact that simple report count performed better than 
SDAs may have been because the reference set comprised known DECs (which in turn may have 
influenced reporting) rather than emerging safety issues, a hypothesis proposed by Noren et al. [34]. 
Inspection of SDA values across child specific strata (age-stratification) revealed some heterogeneity 
in estimates pointing to some effect modification. For example, ‘ibuprofen-thrombocytopenia’, was 
found as a signal in the adolescents’ group but not detected in the entire pediatric population or 
the younger age categories. This suggests that age-specific SDA calculations are sometimes needed, 
rather than age-adjusted SDA estimates. The age-adjusted estimates did not improve performance; 
in fact even PPV unexpectedly decreased. Simulation studies have shown that when adjusted for 
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strata, Bayesian methods such as EBGM tend to be underestimated when there are sparse strata [15]; 
this was also the case in our study. Previous studies in adults show contradictory results, with some 
showing a beneficial effect [9] while others did not [15]. The reason for our finding is not entirely 
clear; a possible explanation is that age is not a strong confounder for the investigated DECs. Also, 
the method of weighting (Mantel-Haenszel approach) may have played a role since more weight 
was assigned to age groups with more reports (adolescents and children). This may have masked 
signals occurring in age groups with fewer reports.
The limitations of data mining in FAERS include those inherent to spontaneous reporting databases: 
underreporting, lack of denominator data and control group, biases in reporting, as well as missing 
and poor quality data [35]. Missing information regarding age substantially reduced the study 
sample size since we could not determine whether these reports described patients aged less than 
18 years old. While these biases are well acknowledged and have a definite impact, they cannot be 
completely avoided. Compared to adults, there are fewer reports and different reporting patterns for 
children [3,36,37] which may complicate signal detection in the pediatric population. 
Evaluating performance of SDAs is a constant challenge due to lack of standard methodologies, 
imperfect reference standards and uncertainty regarding the best thresholds. Some of the drugs 
and events in the reference set are specific to one age group within pediatrics and this is obvious 
in Figure 1, even though the reference set was designed to be relevant for the entire pediatric 
population. We acknowledge that the reference set used, although specifically constructed for this 
purpose, does not include all the ADRs that are highly specific for pediatrics. This highlights the need 
for pediatric-specific approaches to signal detection; accounting for not just the entire pediatric 
population but also the different age strata within pediatrics. Still, the reference set captures various 
drug use and ADRs patterns [38] and is currently the only available pediatric-specific reference set. 
The thresholds applied to define a signal were obtained from previous publications and other cut-
off points may generate better results; further research on pediatric-specific thresholds should be 
encouraged. 
CONCLUSION
Our study revealed that age adjustment did not improve performance of the SDAs. However, 
stratification revealed some variation in SDAs’ values across strata (effect modification) and inspection 
of stratum-specific estimates might sometimes yield useful information during routine surveillance. 
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ABSTRACT
Background and Objectives: In drug safety, there is a lack of guidance on how prioritization of 
safety issues should be performed. The aim of this literature review is to provide an overview of 
criteria used for signal prioritization and of the associated decision support frameworks.
Methods: A search strategy was constructed to identify relevant articles in Medline/Embase 
databases from the period from 1st January 1995–31st August 2015. The prioritization criteria were 
extracted and classified in relevant categories. 
Results: From an initial set of 63 articles, 11 were retained for full review. The articles mentioned 
48 criteria used in the prioritization process, with a median of 6 criteria per study (range: 1–16). 
More than half of the criteria (63%), referred to strength of evidence while 19% related to public 
health impact, 14% to general public and media attention and 4% to novelty of the drug event 
association. Fifteen criteria were tested for predictive value with 11 showing positive results, most of 
them from the strength of evidence category. Six decision making frameworks are presented, which 
incorporate criteria from various categories. Five of these frameworks were tested against expert 
decisions or by other means, but only in one database each and for a limited set of products. 
Conclusions: There is a wide range of prioritization criteria described in the literature, however few 
of them demonstrated predictive value. Many criteria with predictive value were related to strength 
of evidence category and to novelty category. There were few attempts at integrating different 
criteria in decision support frameworks. Five of the frameworks were tested for validity and showed 
usefulness, while at least three are already in use for prioritization.
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INTRODUCTION
Signal management is a key activity in pharmacovigilance, defined as ‘a set of activities performed to 
determine whether, based on a detailed examination of individual case safety reports, aggregated 
data from active surveillance systems or studies, literature information or other data sources, there 
are new risks associated with an active substance or a medicinal product or whether risks have 
changed’ [1]. 
The process starts with an exploratory phase, namely the detection of signals [2]. Hauben and 
Aronson define signal as ‘information which arise from one or multiple sources (including observation 
and experiments), which suggest a new potentially causal association or a new aspect of a known 
association, between an intervention and a set of related events, either adverse or beneficial, which 
would command regulatory, societal or clinical attention, and is judged to be of sufficient likelihood 
to justify verificatory and, when necessary, remedial actions’ [2]. Detection of signals is done in 
several ways, varying from employment statistical methods to a direct review of data by experienced 
professionals [3]. 
Signal detection is followed by several steps of additional data collection and analysis, aimed to 
increase the available evidence and to form the basis for a decision regarding the safety issue. Since 
the amount of detected signals usually surpasses the capacity for analysis, [4] prioritization should 
be done early in the process in order to focus resources on the most important signals, often from 
a public health perspective. 
Similar to the triage applied in a clinical setting, [5] the objectives of prioritization in pharmacovigilance 
context are to ensure that the most important signals (i.e., with highest public health impact) are 
investigated first, to optimize the use of resources and to decrease time from signal detection to 
action. Prioritization is an ongoing process since priority may change in view of newly available 
information. In this study we focused on ‘early prioritization’ or ‘first pass screening’ which is applied 
right after signal detection and before thorough signal evaluation takes place.
Signal prioritization is a multifactorial decision making process, based on a combination of clinical, 
epidemiological, pharmacological and regulatory information. Weighting and integration of 
different information components are human tasks and therefore not always objective since they 
are influenced by prior knowledge and investigator bias [6]. Criteria for signal prioritization are 
suggested in various guidance documents, [3,7] however they are rarely standardized or validated 
[8]. The information available in the field of signal prioritization is scattered and there are no agreed 
criteria or guidance on how to combine them in decision support frameworks [9-11]. 
Therefore, the aim of this literature review is to provide an overview of the existing criteria and 
frameworks for signal prioritization. 
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METHODS
A broad literature search strategy was constructed to identify articles describing criteria for signal 
prioritization. The search was performed in Medline and Embase databases, from 1st of January 1995 
– 31st of August 2015, and restricted to English language. The query was constructed based on MeSH 
terms and keywords extracted from an initial set of relevant publications. This was further optimized 
in an iterative process. 
Articles were initially selected based on title and abstract screening, and subsequently the full text 
article was reviewed. Those that met the inclusion criteria were also checked for cross references of 
relevant studies (‘snowballing’). Articles were included if they referred to one or more prioritization 
criteria used for the prioritization of previously detected signals.
Database Search
(Embase and Medline)
n=63
Title and 
abstract screening
References search and
other sources
n=6
Full test analysis
n=24
13 articles
11 articles
17 articles excluded:
Additional data source: 1
Adjustment of detection method: 8
Causality algorithm: 1
Controlled substances: 2
Other reasons: 5
Re-used the same criteria 
from other included article
n=2
Figure 1: Flowchart of studies selection 
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Some of the variables can be used both in signal detection and prioritization steps. For example 
reporting rate of certain adverse events can be used to flag potential signals however, at the same 
time, an increased reporting rate could be a reason to prioritize a signal for further evaluation. For 
the purpose of this paper, a clear distinction was made and only criteria which were discussed in 
the context of prioritization of already detected signals were included in the analysis. Therefore, 
papers which reported updates of data mining algorithms with additional variables that are meant 
to be used for signal detection were excluded. Similarly, causality assessment methods meant to be 
applied at report level, as the Naranjo scale [12] or the WHO causality assessment system [13] were 
also excluded. 
Data collection
From the included papers the following characteristics were extracted: publication title, year, 
prioritization criteria, its definition and mode of calculation, source and the predictive value (i.e. 
capacity to identify signals which later prove to be true). 
All prioritization criteria were identified from the studies and then categorised independently by two 
authors (AP and LGM). Disagreements were arbitrated by a third reviewer (SS). Categorization was 
done into several pre-defined categories that were selected initially and then modified based on the 
available criteria described in the studies: novelty of drug event association, public health impact, 
strength of evidence, and general public or media attention. The definitions used for classifying the 
criteria into these categories are provided below: 
• Novelty of drug event association referred to an association that was not previously recognised 
or that is not labelled in the product information of the drug [14]. 
• Public health impact was defined as the impact that a potential safety issue is likely to have 
on patients’ health at population level, usually through the number of patients affected by an 
adverse reaction and their consequences [11,15]. The magnitude of the public health impact 
is usually considered in relation to the size of the general population, the population with the 
target disease and the treated population [7]. 
• Strength of evidence was defined as the degree of evidence supporting a causal relationship 
between the drug and the event [16].
• General public and media attention was defined as increased awareness and attention 
from the media or general public regarding a specific safety issue, due to either its serious 
consequences, difficulty to prevent/control or propensity to affect vulnerable populations as 
children or pregnant women [15].
Data analysis 
This is a descriptive study therefore no hypothesis testing was performed. Summary measures for 
categorical data were used for the data description. SPSS version 21 was used for data analysis. The 
decision support frameworks were described individually, due to a large degree of heterogeneity.
519883-L-sub01-bw-Pacurariu
Processed on: 5-6-2018 PDF page: 92
Chapter 5
92
RESULTS 
A total of 63 papers were identified, out of which 11 papers were retained for analysis [4,9-11,15-21] 
(Figure 1). All studies described prioritization of signals arising from spontaneous reporting databases. 
One of the studies [21] focused on drug-drug interactions. A total of 48 different prioritization criteria 
were identified, with a median of 6 criteria per study (range: 1–16) (see Table 1). 
Table 1: Criteria used for signal prioritization and number of occurrences in the literature
Strength of evidence
Disproportionate reporting* 7 Confounded by indication 1
Alternative data sources 4 Mechanism potential 1
Quality/completeness of reports* 4 Narrative present* 1
Rechallenge positive 4 Nested case control studies 1
Multinational reporting* 3 Pharmacological expectedness 1
Biological plausibility 2 Recent reporting* 1
Class effects 2 Plausible CYP metabolism¥ 1
Dechallenge positive 2 Presence of a similar association 1
Typical drug-related event* 2 Reporter qualification 1
Altered therapeutic effect at concomitant use ¥ 1 Reporting rate 1
Alternative cause 1 Specific, characteristic event 1
Rapid reporting increase* 1  Unexpected therapeutic response ¥ 1
Background frequency 1 Suspected interaction by reporter¥ 1
Fractional reporting ratio 1 Targeted comparisons 1
Causality 1 Temporality 1
Public health impact General public and media attention 
Seriousness* 6  Factors likely to cause public anxiety 1
Number of reports 5 Media attention 1
Drug exposure 2 Other public concern 1
Frequency of ADR in users 2 Public misperceptions 1
Potential for prevention 2 External interest 1
Potential health consequences 2 Health authority concerns 1
Critical term* 1 Recent parliamentary questions 1
Targeted medical events 1
Severity 1
Novelty
Novelty of the drug event association* 4
Novelty of the drug * 2
ADR=adverse drug reaction; * Demonstrated predictive value (i.e., capacity to identify signals which upon further 
analysis were proven to be true); ¥ Applicable only to drug-drug interactions
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More than half of prioritization criteria referred to strength of evidence (63%), while 19% related to 
public health impact, 14% to general public and media attention and 4% to novelty of the drug 
event association (see Table 2). The most frequently used criteria were disproportionate reporting 
(7 studies), seriousness (6 studies) and number of reports (5 studies). 
Six studies combined multiple criteria into decision support frameworks.
Table 2: Description of prioritization criteria
Count Percentage
Category 
Strength of evidence 30 63%
Public health impact 9 19%
Novelty of drug event association 2 4%
General public and media attention 7 8%
Source of the criteria
Spontaneous reporting databases 23 48%
Drug utilisation data 3 6%
Product information 2 4%
Other data sources 27 56%
Predictive value tested (Yes) 15 31%
Percentages do not add to 100 since some variables can have more than one source
Criteria related to strength of evidence 
Thirty different criteria related to strength of evidence were reported in 10 studies, with the most 
frequently reported ones being: disproportionate reporting, alternative data sources confirming 
the signal, quality/degree of completeness of reports and positive rechallenge. In addition to the 
disproportionality measures, rapid reporting increase [9,16] and recent reporting [10] were also 
categorised as related to strength of evidence. 
An important criterion was the quality and completeness of reports. Two independent studies have 
shown a correlation between the quality of reports and true signals [10,17]. Caster et al. used two 
different criteria related to the quality/completeness of reports, one being a completeness score and 
the other a dichotomous criterion which indicates if the narrative is present or not in the report [10].
Another criterion is multi-national reporting (i.e., reports of a specific drug-event association 
originating from different countries; this increased the probability that the signal is true [9,10].
A third important criterion related to the strength of evidence was use of additional data sources. 
Some authors mentioned pre-clinical, clinical or epidemiological studies, [14,20] while others 
considered only randomized clinical trials or meta-analysis of clinical trials to be valuable sources 
of evidence [15]. 
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Criteria related to novelty
Two criteria were identified that relate to novelty: novelty of drug event association and novelty of 
drug. Novelty of the drug event association was mentioned as a criterion to prioritize signals in four 
studies [14,16,17,20]. The novelty was usually assessed by checking if the ADR is mentioned in the 
product information or other sources of safety data, such as scientific literature, medical textbooks 
or Pharmacopoeias. One study [17] proved that true signals are correlated with absence of the ADR 
from the product information. 
The novelty of drug (i.e., time on the market) was also used in prioritization [9,17] and showed 
predictive value. Instead of using it as a continuous variable, it was dichotomized in new vs. old 
drugs, according to an empirically chosen threshold: in one study a threshold of five years was 
chosen, while in another one, the threshold was 2 years. 
Criteria related to public health impact 
Nine criteria related to public health impact were identified in eight studies. The most frequent 
criteria were seriousness, drug exposure and number of reports. 
Firstly, the seriousness of the reports was the most often used criterion (n=6), and also showed 
predictive value [9,17]. Studies that attempted to quantify the seriousness of the reports divided it 
into a fatal component and a non-fatal component (e.g., potential to cause major/permanent or 
minor disabilities). 
Secondly, the extent of drug exposure was used to estimate health impact [15,18]. The pre-defined 
threshold of drug exposure that was used in the different studies to decide if an issue has a potential 
high public health impact varied from a threshold of 100,000 exposed patients/year (United 
Kingdom) [15] to over 1 million patients exposed cumulatively (United States) [18].
Thirdly, the absolute number of reports was another frequently used criterion for health impact 
[11,14-16]. Usually, the higher number of reports, the higher the health impact. The paper by Stahl et 
al. introduced an unusual threshold to the number of reports, which described a maximum instead 
of a minimum of reports as a prioritization criterion [9]. This criterion was developed for VigiBase®, 
the WHO international database of suspected adverse drug reactions maintained by UMC on behalf 
of the WHO Programme for International Drug Monitoring. 
Except these three main factors, public health impact could have been assessed in other ways as 
well. Some organizations developed lists of ‘drug related events’ and ‘targeted medical events’, based 
on event seriousness and its likelihood to be drug induced. Examples are: targeted medical events 
developed by Food and Drug administration (FDA), [22] the critical terms list developed by UMC 
[23,24] and the important medical events list developed and maintained by EudraVigilance Expert 
Working Group in collaboration with MedDRA®. It was demonstrated that ADR being a critical term 
was predictive of a true signal [9,17]. 
519883-L-sub01-bw-Pacurariu
Processed on: 5-6-2018 PDF page: 95
After signal detection: prioritization and triage
95
5
The potential for prevention was also taken into account in two studies, [14,20] however none of 
these studies explained this any further nor described exactly how the concept can be evaluated 
or measured. 
Criteria related to general public and media attention
Potential public misperceptions about the safety of the drug could cause harm through a behaviour 
change (e.g. decreased vaccine uptake, abrupt discontinuation of medicine leading to poor 
outcomes) [15] and therefore should be considered during signal evaluation. Factors likely to cause 
public anxiety either due to serious consequences of the reaction, difficulty to prevent/control the 
hazard or signals that are likely to affect vulnerable populations such as children/pregnant women 
were mentioned. In several studies the presence of external interest from media, health authorities, 
scientific community or patients was taken into account [15,16].
Predictive value of criteria
The predictive value of 15 prioritisation criteria was evaluated in five studies [9,10,17,19,21] and eleven 
criteria predicted real signals to a certain extent. Various approaches were used to evaluate the 
predictive value of criteria, for example logistic regression models or comparison with an alternative 
gold-standard method (e.g., expert review). 
Many criteria with predictive value were related to strength of evidence category (rapid reporting 
increase, recent reporting, disproportionate reporting, multinational reporting, quality/degree of 
completeness reports, and presence of narrative in the reports). Both criteria categorised under 
novelty were shown to have predictive value (novelty of the drug and novelty of drug event 
association). From public health impact category, two criteria, namely seriousness and ADR being a 
critical term were shown to have predictive value. 
Four criteria which failed to show predictive value were: positive dechallenge and positive 
rechallenge, number of reports and reporter qualification. The rest of them have not been tested. 
Frameworks for signal prioritization 
Six decision support frameworks were identified in the literature (see Table 3) and all of these contain 
a mix of the criteria presented above. Some introduced graded scales to limit subjectivity [11,15,16] 
and some included weighting schemes, [10,11,15,16] assigning more importance to some criteria 
than to others. 
Five of the frameworks were tested to see how well they predict signals. This was done by calculation 
of agreement coefficients [11,15,16] or by regression models [10]. The gold standard against which 
evaluation was made consisted of reference sets of either known signals or expert judgment. 
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The initial prioritization algorithm was developed by Stahl et al. [9] as early as 2001 at UMC, and took 
into account rapid reporting increase, seriousness, time on the market for the involved drug and 
if the ADR was of special interest. It was mentioned that these criteria proved to be successful in 
selecting true signals, however the exact testing method was not provided. 
Another decision support framework [11] took into account the strength of evidence and 
the potential public health impact. The included components of strength of evidence were: 
disproportionality score, quality of reports and biological plausibility. The components of public 
health score were: number of reports, seriousness and reporting rate. Using an empirical cut-off 
point for both scales, four priority categories for a signal were obtained, each having a different 
course of regulatory action. All subjective variables were quantified using graded scales. This tool 
was validated [25] and is currently used for prioritization in a regulatory setting at Medicines and 
Healthcare Products Regulatory Agency (MHRA) in the UK. 
Seabroke et al. [15] updated the framework mentioned above by adding two categories: agency 
regulatory obligations and public perceptions. This updated tool was designed to be used in a later 
stage of signal management. The tool was piloted and validated against expert group opinion and 
is also routinely used in the same organization. 
A multi criteria decision analysis (MCDA) weighted framework was developed by Levitan et al. [16] 
based on 11 criteria related to novelty of event (10% weight), strength of evidence (40% weight) and 
medical impact (50% weight). In addition, two extra criteria were used for pre-selection: evaluation 
of novelty of the event and of confounding by indication. Each criterion had an assigned weight and 
there were graded scales for each attribute. The model was tested against expert group judgment 
and the agreement was found to be moderate. 
FDA drafted a prioritization guidance aimed to classify post-marketing drug safety issues [18]. This 
guidance recommends to estimate the hazard posed by a safety issue, based on three criteria: (1) 
the seriousness of the issue; (2) the estimated size of the population exposed to the drug; and (3) 
the suspected frequency of harm for exposed patients. The combination of factors 2 and 3 provides 
an estimate of population risk, while the combination of factors 1 and 3 provides an estimate of 
individual risk. 
The vigiRank predictive model developed by Caster et al. [10] is an algorithm for emerging safety 
signals that accounts mainly for reports quality and content. The following criteria were included: 
disproportionate reporting, number of informative and recent reports, number of reports with a 
narrative and multinational reporting. The advantages of this method are that it is automated in 
VigiBase® and was tested in a comprehensive manner, by means of multiple logistic regression, 
and against a reasonably large reference set. Public health impact was not considered within this 
algorithm. 
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Last but not least, Strandell et al. [21] propose two prioritization frameworks specific to drug-drug 
interactions. This was the first application of predictive regression models for first-pass screening of 
large collections of spontaneous reports, when looking for drug interactions. Due to its specificity for 
drug interaction, this was not described further.
DISCUSSION 
Prioritization decisions are typically complex and resource intensive, as they blend the numerical 
information with scientific knowledge and judgment [8]. In this paper, we conducted a review of 
signal prioritization criteria and associated decision support frameworks that were built upon those, 
in order to increase awareness and facilitate the process. 
A total of 48 criteria were identified in the literature for signal prioritization, and they were categorized 
according to the following key concepts: novelty, strength of evidence, public health impact and 
general public and media attention. 
One important distinction should be made early on regarding the criteria found in the studies: 
some of them were used for prioritization based on their predictive value, while others were used 
independent of this property. Usually, criteria related to strength of evidence would fall in the first 
category, whereas criteria related to public health impact would be included in the second one. 
The novelty concept is intrinsic to signal definition and six studies mentioned it, albeit this might be 
an underestimate of its actual use in signal prioritisation process. Novelty could related to the drug 
event association or just to the drug. Although ‘Weber effect’ [26] (i.e., AE reporting peaks at the end 
of the second year after approval) was not reproduced, [27,28] two studies [9,17] showed that new 
drugs are more likely to have more safety signals. 
Another key concept, strength of evidence, was at the core of prioritization algorithms, being 
considered by 10 out of 11 studies and by all six decision support frameworks. This was expected, 
since it is logical to focus the resources, even from a very early stage, on those signals which have 
a high probability to be true. From the strength of evidence related criteria, the multi-national 
reporting was repeatedly demonstrated to have predictive value [9,10]. In addition, the quality of 
reports predicted a true signal and, therefore, it is worthwhile to consider this when prioritizing. 
The fact that the report quality/completeness is associated with true signals might seem counter-
intuitive at first, since an increase in the amount of information should not necessarily mean an 
increase in likelihood of a causal association. A potential explanation might be that the reporter is 
more likely to provide more complete information about a report once he genuinely believes that 
the drug is the real culprit. An alternative possibility is that only complete reports can provide the 
necessary information for a causality assessment that can give rise to a true signal.
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Besides focusing resources on true signals, a second purpose of prioritization process is to give 
precedence to signals with a higher public health impact [11]. Public health impact criteria can have 
a contribution as high as 50% [16] in decision support frameworks and it might well happen that 
weaker signals from an aetiological perspective will gain a higher priority, based on their potential 
impact on public health [11]. When estimating the public health impact, the number of reports 
and drug exposure data are deemed to be essential and are incorporated in various measures 
across studies. Waller et al. [11] highlights that in some situations the drug exposure variable might 
underestimate the importance of the signal when the drug use is limited to a particular sub-
population, and suggest that in these situations a correction factor should be applied. 
Criteria were rarely tested for predictive value (31%), mainly because it is particularly difficult to 
create a benchmark against which to perform testing. On the other hand, as previously mentioned, 
not all prioritization variables need to have predictive value. Most of the criteria are complementary 
and can be used in combination. As with any decision support system, an increase in the number 
of variables taken into account might enhance the accuracy of the decision, provided that the 
variables are fit for purpose and the data is of good quality. It appears that a combination of criteria 
from all four main key concepts (e.g. novelty, strength of evidence public health impact and general 
public/media attention) is necessary for a robust decision, however the specific choice of the criteria 
within these concepts is less straightforward. 
CONCLUSIONS 
There is a wide range of prioritization criteria described in the literature, however few of them 
demonstrated predictive value. Many criteria with predictive value were related to strength 
of evidence category (rapid reporting increase, recent reporting, disproportionate reporting, 
multinational reporting, quality/degree of completeness reports, presence of narrative in the 
reports) and to novelty (novelty of the drug and novelty of drug event association). Using these 
criteria is likely to increase the number of true signals in the post-prioritization set. 
There were few attempts at integrating different criteria in decision support frameworks. Five of the 
frameworks were tested for validity and showed usefulness, while at least three are already in use for 
prioritization [10,11,15]. 
We recommend more testing of currently available prioritization criteria and frameworks as this 
would support creation of a robust evidence-based prioritization process. Testing should be done 
through comparison with existing prioritization procedures, in order to ensure that important 
signals are not missed by the updated process.
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ABSTRACT 
Background and Objectives: The amount of drug exposure, pre and post approval, is considered 
to be a direct determinant of knowledge about safety of a drug. A larger pre-approval exposed 
population is supposed to reduce the risk of unanticipated safety issues post-approval. Post-approval 
population should also influence the number and occurrences of safety issues. We investigated how 
the amount of pre and post approval exposure influences the occurrence of safety issues post-
approval. 
Methods: Analysis was performed on a group of newly approved drugs in Europe, monitored for 
a median time of median time of 15.8 months. The outcome of interest was the first safety issue 
occurred in the period. We use a Cox model applied for analysis and we adjusted for drug related 
characteristics which were considered to be confounders.
Results: The amount of pre-approval exposure was not associated with the risk of safety issues 
when adjusting for anatomical therapeutical chemical (ATC) class, biological status and treatment 
duration. The post-approval exposure was associated with the risk of new safety issues (HR=2.44 
(95%CI=1.12–5.31)) for drugs with more than 1,000 patient-years of cumulative exposure compared 
to drugs with less than 1,000 patient years of exposure.
Conclusion: Our results suggest that low pre-approval exposure does not lead to more post-
approval safety issues while post-approval exposure influences to some extent the occurrence of 
safety issues. 
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INTRODUCTION
Traditionally the lifecycle of a drug is split into two main phases: the pre-approval phase when all 
of the exposure occurs during randomized clinical trials and the post-approval phase when most 
exposure occurs during so-called “real-world” use. Despite interest in more iterative approaches 
that might facilitate the access to innovative drugs for patients with unmet medical needs, [1] the 
traditional pre- to post dichotomy remains the norm. 
Medicines regulators grant a marketing authorization for a new drug based on the assessment of 
the product’s safety, quality and efficacy and the judgment that the benefits outweigh the risks for 
the target population and in the respective indication. However, at market entry, the knowledge of 
the product’s safety profile is restricted due to the well-known limitations of pre-approval clinical 
trials [2]. Due to strict inclusion criteria, clinical trials often include a smaller, healthier and more 
homogenous population than the one for which the drug is intended post-approval. The total pre-
approval exposure consists of a median of 1,700 patients [3]. In addition, the follow-up duration may 
be shorter than the intended drug use and consequently, adverse drug reactions (ADRs) with longer 
latency may be missed [3].
After approval, the initial safety profile is complemented with ADRs which occur and are detected 
post-approval, during the use of the product in the “real-world” setting. For this article, the terms 
occurrence and detection (of a safety issue) will be used interchangeably, the term “detection” being 
a proxy for “occurrence”. Usually the post-approval population is larger and more heterogeneous 
than pre-approval population and its composition is influenced by various drug characteristics such 
as intended duration of treatment, drug legal status, target population and approved indication. 
The amount of patients exposed to a drug is considered a direct and critical determinant for 
the knowledge on safety, [4,5] however there are only few studies which have investigated this 
relationship. One might expect that a larger pre-approval population will lead to a better established 
safety profile at market entry and consequently fewer safety issues detected post-approval. On the 
contrary, the post-approval population is supposed to directly influence the number and speed of 
occurrence of safety issues, mainly by increasing the sample size. Neither of these hypotheses is 
completely clarified at the moment. 
One study conducted in Europe found that a larger pre-approval exposure leads to more serious 
safety issues post-approval and that the magnitude of post-approval exposure does not influence 
the occurrence of safety issues [6]. A second study [7] found that an important amount of safety 
signals occurs during the first 18 months post-approval, regardless of whether the product met a 
pre-defined exposure threshold of 10,000 patients or not; therefore the authors have concluded that 
post-approval exposure does not influence markedly the occurrence of safety issues. A third study 
tried to predict the amount of exposure needed to detect safety signals in electronic healthcare 
records and showed that the exposure is a function of the minimal detectable risk and background 
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incidence of the ADRs to be detected [4]. The study showed that the power to detect new safety 
issues is low for drugs with limited exposure [4].
In view of the limited existing research, the question of how pre and post-approval exposure to 
a drug influences the occurrence of safety issues post-approval is not yet completely answered. 
Clarification is relevant for regulators and pharmacovigilance specialists since this would inform 
policy-making, decisions on the authorization of new medicines, and would enable risk proportionate 
safety monitoring, with priority given to the drugs that are more likely to be associated with safety 
issues. This would further support risk management planning by targeting signal detection and 
post-authorization studies on situations where safety issues are most likely to occur. 
This study was designed to address the question whether drug exposure is associated or not 
with the occurrence of new safety issues. We focused on newly approved drugs, expecting that 
any influence of exposure will be most pronounced during the first period on the market. Despite 
limited knowledge about their safety profile, new drugs might have a very rapid market uptake 
due to unmet medical need [6,8] and they might also be channeled to sicker patients who did not 
respond to existing alternatives. 
Objectives
In this study we investigated if the amount of pre and post approval exposure is associated with the 
frequency and time to occurrence of safety issues post-approval. 
METHODS
Study design and data collection 
All innovative drugs, [12] approved in Europe by the European Commission between 1st January 
2012–1st January 2016, were retrospectively studied. Both biological and small molecules were 
included. Scientific and regulatory information about drugs was obtained from the publicly 
available European Public Assessment Reports (EPARs), [13] which are summaries of drug related 
data compiled at the moment of authorization. 
The main outcome of interest was whether the drug had a new safety issue in the period. We 
defined a new safety issue as occurrence of a new ADR or an increase of frequency or severity of a 
known ADR, which led to updates of the SmPCs, so-called “variations”. Safety-related variations were 
identified from the website of the European Medicines Agency (EMA) [14]. For the scope of our 
research, we only included changes in the sections “Undesirable effects”, and “Special warnings and 
precautions for use”. Safety related changes that were the result of an extension of the indication or 
minor changes as a result of misspellings and correction of errors were not considered as outcome. 
The official date of completion of the variation was captured as the date of occurrence of the 
outcome. If mentioned, the source of information (spontaneous databases, clinical trials, other) 
substantiating the changes was recorded. 
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The drugs were followed until the earliest occurrence of the following: first new safety issue (addition 
of ADR to the SmPC), suspension/withdrawal of drug for safety reasons or end of study period.
Pre-approval exposure was defined as the cumulative number of patients and healthy volunteers 
exposed to the product in all clinical trials conducted as part of the clinical development program, 
as described in the scientific discussion of the EPARs [13]. 
Post-approval exposure was defined as the number of patient-years of exposure after approval and 
was calculated based on sales data. Sales data were obtained from periodic safety update reports 
provided by the marketing authorization holders. Post-approval exposure is a time dependent 
variable, and was recorded at fixed time points during a drug lifecycle: every 6 months for the first 
three years on the market. The values of post-approval exposure at intermediate time points were 
imputed by a simple linear interpolation between the two closest reported values. 
Other characteristics collected for the included drugs were ATC class, biological status, orphan status 
and type of approval (e.g., regular approval vs. conditional approvals or approval under exceptional 
circumstances). In Europe there are two different types of approval, besides the regular one: 
exceptional circumstances (EC) [15] and conditional approval (CA), [16] both allowing drugs to be 
approved on more limited clinical datasets in order to fulfil unmet medical need. 
Analysis 
Descriptive statistics were used to characterize the drugs. Differences in baseline characteristics 
across exposure categories were tested with chi-square tests for categorical data and Mann 
Whitney-U test for continuous data.
Since the hazard of finding a new ADR is time dependent, [17,18] Kaplan-Meier survival analysis was 
used to estimate the probability of the occurrence of a first safety issue post-approval at 12 and 36 
months respectively as well as the time from the approval date to a first safety issue. 
We used Cox proportional hazards regression model to investigate the association between exposure 
variables and the hazard of having a first safety issue. Pre-approval exposure was incorporated as a 
fixed variable, collected at the beginning of follow up (e.g., time when the product was placed on 
the market), while post-approval exposure was incorporated as a time dependent variable, with the 
last value collected at time of the outcome or censoring. Both exposure variables were transformed 
from continuous into categorical, to make the results easier to interpret from a clinical perspective. 
Sensitivity analysis was performed by including all variables which differed significantly between 
exposure categories and which were considered to be potential confounders based on clinical 
judgment and previous research [6,10,19]. SPSS version 21 and R version 3.3.1 were used for analysis. 
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RESULTS 
A total of 233 drugs were centrally approved in European Union during the study period. After 
applying the exclusion criteria, 136 drugs were retained in the analysis and monitored for a median 
time of 15.8 months (interquartile range (IQR): 8–26) (see Figure 1).
The three most prevalent drug categories were Antineoplastic and immune-modulating agents 
(32%), Alimentary tract and metabolism (14%) and Anti-infectives for systemic use (12%). A third of 
the drugs were orphans (29%) and slightly more than one third (34%) were biological drugs. Other 
key characteristics of the included drugs are presented in Table 1. 
Total number of approved drugs via centralised
procedure at EMA
January 2012-December 2015
n=233
Excluded
Hybrid applications, well-established use,
extension of indication (n=61)
Diagnostic products, radio pharma
precusors or radiotherapy (n=6)
Vaccines (n=5)
Fixed dose combinationwith previously
approved substancesb (n=22)
Excluded
Withdrawn for 
commercial reasons 
(n=3)
Total number of 
analysed drugs
n=136
Figure 1: Attrition chart for study drugs 
a- Approved under article 10(a), 10(c) or 10(3) of Directive 2001/83/EC 
b- Approved under Article 10(b) of Directive 2001/83/EC
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Table 1: Key characteristics of investigated drugs 
Variable All drugs 
 (n=136)
ATC class a
Antineoplastic and immune- modulating agents 44 (32%)
Alimentary tract and metabolism 19 (14%)
Anti-infectives for systemic use 17 (12%)
Other 56 (41%)
Indication b
Type 2 diabetes mellitus 17 (12%)
Chronic obstructive pulmonary disease 8 (6%)
Chronic hepatitis C 6 (4%)
HIV infection 6 (4%)
Multiple sclerosis 6 (4%)
Prostate cancer 5 (4%)
Treatment duration 
Short term 14 (10%)
Medium term 49 (36%)
Long term 71 (52%)
Biological (Y) 46 (34%)
Orphan drugs (Y) 40 (29%)
Exposure related variables
Pre-approval exposure (patients), median, (IQR) 1,111 (445–2,166)
0-500 39 (29%)
500-2,000 59 (43%)
>2,000 38 (28%)
Post-approval exposure (patient-years) median, (IQR) 1,076 (89–12,560)
<1,000 36 (50%)
1,000-10,000 15 (21%)
>10,000 21 (29%)
Procedural aspects 
EC and CA registration (Y), n (%) 20 (15%)
Total follow up time, months, median, IQR (range)c 15.8 (8–26)
Number of newly added ADRs per drug, median, ranged 2 (0–11)
ATC=anatomic therapeutic chemical; IQR=interquartile range; EC=exceptional circumstances, CA=conditional approval; 
a Three classes (A, J, L) comprise more than 50% of the drugs and are therefore separately presented, the rest are 
grouped in the category “other”; b Only indications with 5 occurrences are presented; c Follow up time is measured until 
first outcome, study end or drug withdrawal; d Multiple ADRs added within the same regulatory procedure (grouped 
variations) were included as separate occurrences
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The drugs had a median pre-approval exposure of 1,111 patients (IQR: 445–2,166) and a median 
cumulative post-approval exposure of 1,076 patient-years (IQR: 89–2,560) (see Figure 2). 
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Figure 2: Pre-approval and post-approval exposure across different drug categories
A pre-approval exposure; B- post-approval exposure. Standard category is represented by drugs which do not belong 
to any of mentioned categories (i.e. non-orphan, non-biological and approved via a regular procedure). The other three 
categories are not mutually exclusive. The dots represent outliers.
During the period under review, 104 new ADRs were added to the SmPC of 35 drugs. Out of these, 
four (3.8%) were not new but known ADRs with increased frequency of occurrence. The most 
frequently identified ADRs referred to gastrointestinal disorders (15%), skin and subcutaneous tissue 
disorders (11.4%) and immune system disorders (11.4%). Three withdrawals for commercial reasons 
took place during the study period and no drugs were withdrawn because of safety reasons. 
The cumulative hazard (Kaplan-Meier probability) of a drug having its first ADRs added to the SmPC 
was 10.4% (95%CI=4.6%–15.9%) in the first year after approval and increased to 47.7% (95%CI=31%–
60.3%), three years after approval. 
The pre-approval exposure appeared to be correlated with the risk of having an ADR added to 
the SmPC post-approval, in the first 2 years after approval; in the unadjusted model the risk being 
almost double (hazard rate (HR)=2.0 (95%CI =1.17–3.44)) for drugs with more than 2,000 patients 
exposed in clinical trials, compared with drugs with less exposure. However, the relationship was not 
maintained in the adjusted model (see Table 2), where the HR decreased to 1.28 (95%CI=0.55–2.46). 
The amount of post-approval exposure was associated with the risk of having an ADR added to 
the SmPC in the first 2 years after approval; drugs with more than 1,000 patient-years of cumulative 
exposure had a higher risk of SmPC updates (HR=2.58 (95%CI=1.39–4.77)) as compared to drugs 
with less than 1,000 patient years of exposure. At very high levels of post-exposure (>10,000 patient-
years) the risk starts to decrease but is still higher than for drugs in the lowest exposure category. 
The relationship was maintained after adjustment; HRs just decreased slightly compared to the non-
adjusted model (see Table 2). 
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Table 2: Results of Cox proportional hazards regression analysis 
Exposure related variables HR crude model
(95%CI)
HR adjusted model a
(95%CI)
Pre-approval exposure (patients)
≤500 Reference Reference
>500 and <2,000 1.18 (0.69–2.01) 1.17 (0.55–2.46)
≥2,000 2.00 (1.17–3.43) 1.28 (0.54–3.04)
Post-approval exposure (patient-years)
<1,000 Reference Reference
≥1,000 and <10,000 2.58 (1.39–4.77) 2.44 (1.12–5.31)
≥10,000 0.86 (1.01–3.44) 1.29 (0.47–0.97)
HR=hazard rates; a adjusted for post/pre-exposure, biological status and ATC class
A secondary analysis using other variables potentially associated both with exposure and the 
safety issues, showed that drugs which are antineoplastic and immune-modulating agents, drugs 
indicated for acute treatment and non-biological drugs also had an increased risk of safety issues 
post-approval, independent of the exposure. 
DISCUSSION
We initiated this study with the aim to test whether the hypothesis that the amount of patients 
exposed to a drug is associated with the occurrence of safety issues. So far, only one study [5]
concluded that the amount of patients exposed is an important determinant of the statistical power 
for detection of safety signals post-marketing. Solely from a statistical perspective this might sound 
obvious. However, the post-approval setting is complex and therefore the amount of exposure 
might influence the safety in multiple and sometimes contradictory ways. 
We were expecting that pre-approval exposure will be inversely correlated with post-approval 
safety issues due to the fact that a well-established safety profile at market entry will leave little 
room for new signals to be discovered post-approval. In our study, the initially increased risk for 
products with higher pre-approval exposure disappeared after adjustment for other drug related 
characteristics such as ATC class, treatment duration and biological status, suggesting that the 
amount of pre-approval exposure is not an independent risk factor for occurrence of post-approval 
safety issues. An explanation for this finding might be that the variation in pre-approval exposure is 
largely determined by the nature of the product and once we have accounted for this, the apparent 
relationship to post-approval safety disappears; therefore it is more likely that pre-approval exposure 
is a confounder or intermediate rather that an independent risk factor for safety issues. 
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Secondly, we hypothesized that post-approval exposure will be directly correlated with post-
approval safety issues; the higher the exposure, the more safety issues will be found. Our results 
confirmed this second hypothesis; drugs with more than 1,000 patient-years of exposure had a 2.5 
higher risk of having a safety related change in the SmPC compared to drugs with less exposure. This 
relationship was observed up to a certain exposure threshold (approximately 10,000 patient-years), 
after which the risk reached a plateau and then started to decrease, suggesting a non-monotonic 
relationship between post-approval exposure and occurrence of safety issues. The relationship 
remained similar after adjustment for other variables, increasing the robustness of our finding. Our 
results are opposing those from an earlier study which failed to find an association between post-
approval exposure and occurrence of safety issues [6]. The discrepancy might be explained by use of 
different outcome definitions and different cut-off points for the exposure categories. Moreover, in 
the study by Mol et al., [6] the exposure data was collected only from one country (the Netherlands), 
while our exposure variable reflects worldwide exposure. Another study, [7] found that an important 
amount of safety signals occurs during the first 18-months post-approval, regardless of whether the 
product met a predefined threshold of 10,000-patient or not. This is partly in line with our results 
since for higher values of exposure we also found that the risk starts to decrease. 
A secondary finding from our study referred to other drug related variables which might influence 
the hazard of having a safety issue. For example, some ATC classes might be associated with an 
increased risk of safety issues. In our study this ATC class was Antineoplastic and immune-modulating 
agents. The same result was reported before [6,9]. This finding must be interpreted with caution 
since a contributor factor might have been the over representation of this ATC class in the group of 
drugs even from the study start. Drugs indicated for acute treatment and non-biological drugs also 
had a slightly increased risk of safety issues, independent of exposure. On the contrary, the orphan 
drugs did not appear to have an increased risk, this also being in line with previous research [9]. The 
same lack of increased risk was found for drugs with exceptional or conditional approval [10].
Another secondary finding was that the most frequent ADRs added to the SmPC of new drugs in 
the first 2 years on the market were related to gastrointestinal disorders, skin and subcutaneous 
system disorders and immune system disorders. This is different from what was reported for all 
drugs (including both new and old drugs) for which the most common signals were related to 
general disorders and administration site conditions, nervous system disorders and gastrointestinal 
disorders [11]. Considering this difference, one might speculate that the type of reactions added to 
the SmPC change over time, and they also differ between new and old drugs, but we did not test 
formally this hypothesis in our study. 
A few limitations of our study need to be mentioned. A first limitation is the relatively small sample size 
and few safety issues leading to lack of precision of estimates and potential false negative findings. A 
second limitation is the fact that we used the time of approval as a proxy for time of marketing, since 
the exact time of marketing is difficult to obtain. This led to a potential initial follow-up period during 
which no exposure occurred, however this is expected to be non-differential across groups and 
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therefore likely to affect just the precision and not the magnitude of the estimate. A third limitation 
pertains to the post approval variable; due to the fact that only values at specific time points were 
available we needed to impute missing values, which might have reduced the variability of data or 
have biased the variable in other ways. However we consider that the imputation method we used 
(simple linear interpolation between the closest existing values) is adequate, considering the short 
time period between the known exposure time points. 
A strength of our study was the use of a statistical model which took the follow-up time into account, 
since both exposure and safety outcomes are known to be time dependent. To our knowledge this 
is the first study which investigated the relationship between exposure and safety outcome as its 
main analysis. 
In conclusion, low pre-approval exposure does not lead to faster or more frequent post-approval 
safety issues, being rather an intermediate factor. The finding that pre-approval exposure does not 
influence the number of safety issues discovered post-approval confirms the idea that increasing 
the size of pre-approval population will not answer all the safety questions. 
On the other hand, the amount of post-approval exposure is a clear determinant of the appearance 
of post-approval safety issues, at least in the first period on the market and until a certain exposure 
threshold is reached. Considering this finding, our recommendation is that the amount of patients 
likely to be exposed to a drug post-approval should be considered when planning the post-approval 
safety monitoring. Special consideration should be given to drugs with potential for high and rapid 
market uptake and to antineoplastic drugs. We would also recommend extending the study of the 
relationship between exposure and the timing, number and type of safety issues to a larger drug 
sample, as a better understanding of this relationship is likely to drive process improvement in risk 
management planning.
We consider that our study contributes to measuring the impact of pharmacovigilance, a key activity 
in driving process improvement.
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SUMMARY OF FINDINGS 
This thesis comprises studies that aim to answer questions related to sub-domains of signal 
management and regulatory science: data sources, detection methods, and the prioritisation 
process.
We started this thesis with a review of signals detected in the EU, as major legislative changes were 
adopted in 2010 and implemented in 2012. Based on the review of signals discussed in the PRAC 
we found that, similar to the USA, the most frequently used data source was spontaneous reports 
(72% of cases), see Chapter 2 [1]. The most frequently discussed signals were related to skin and 
subcutaneous tissue disorders (12.8%), nervous system disorders (10.4%) and cardiac disorders 
and immune system disorders (6.4%). We observed that the mean time between a new signal 
occurrence and a decision by PRAC was 2.5 months, with 42.8% of all decisions taken during the 
first meeting. For 57.2% of the signals, additional information about the signal was requested after 
the first discussion in the PRAC. Several actions can be taken in relation to a newly validated signal. 
The decision most often taken was a change in the product information (54%). The decisions to 
start a referral and to send a direct healthcare professional communication, which are usually taken 
for more serious and urgent issues, were not that common (9.4 % and 7.3%); however they were 
decided more rapidly (1.8 months and 1.7 months, respectively).
Although spontaneous reports are still the mainstay for signal generation, their limitations are well-
known and in view of these, additional data sources to augment signal detection are constantly 
being sought. After several large impact drug safety issues in the beginning of the new century the 
Institute of Medicine recognized that reliance on spontaneous reports alone may not be enough 
and suggested that potential electronic healthcare records (EHRs) may be used as alternative 
source [2]. To explore how EHRs can complement spontaneous reports in safety surveillance we 
investigated the role of European EHRs as a signal generation source and compared the ability 
to detect known associations between the databases participating in the EU-ADR project with 
Eudravigilance in Chapter 3.1. In this study, spontaneous reporting systems SRS outperformed EHRs 
in signal detection for events with a rare to very rare background incidence and ADRs which are 
easily attributable to drugs, e.g. bullous eruption and acute pancreatitis. On the other hand, there 
were events (e.g. hip fracture) for which detection in EHR led to better results. 
An important issue to be taken into account when deciding which data source to use for signal 
generation is the noise-to-signal ratio. The false-positives associated with detection of signals in 
each data source (EU-ADR and EudraVigilance) depend both on the type of events and on the data 
source. Across the events, the lowest number of false positives was found for upper gastrointestinal 
bleeding and acute pancreatitis and the highest for bullous eruption. In terms of databases, for all 
events, it was more costly (e.g., more false positives need to be discarded) to detect safety signals 
in EHRs than in spontaneous reporting systems. In conclusion, an EHR-based system may have 
additional value for signal detection, alongside already established systems, especially for adverse 
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events with high background incidence. At this moment, spontaneous reporting systems appear to 
be more cost-effective than EHRs. 
In Chapter 3.2, we described the use of EHR for signal evaluation by studying the association 
between triptans and ischaemic colitis. Due to the rarity of the outcome, only a few anecdotal 
reports have been reported to date. In the THIN primary care database, which covers ~6% of the 
UK population, we identified only 41 incident cases of ischemic colitis within a migraine cohort 
of approximately 300,000 patients. Use of triptans in the 12 months before the event, doubled 
the risk of ischemic colitis compared to no use (OR=2.29, 95%CI 1.02–5.15). After 12 months, the 
risk decreased to (OR=1.90, 95%CI 0.44–8.13). The lack of power restricted us to further investigate 
alternative exposure windows.
Apart from using different data sources as the basis for signal detection/evaluation, we investigated 
how to improve the performance of existing signal detection methods in paediatrics. In Chapter 
4.1 we tested the impact of age stratification or adjustment on signal detection performance. Two 
algorithms (PRR and EBGM) were applied to reports in children < 18 years of age, where the impact of 
age is expected to be higher due to organ maturation by age [3]. Performance was similar between 
methods (measured by area under the curve (AUC). Age adjustment decreased the performance of 
both methods compared to the unadjusted scenario. Stratification by age group, unmasked new 
signals in specific age strata, which were not discovered in the overall paediatric population analysis. 
We observed that age can be an effect modifier and therefore should be stratified for. 
To increase efficiency and reduce the noise-to-signal ratio it may be useful to understand which type 
of drugs have a higher risk of new safety signals. Drugs for which a new signal was discussed at PRAC 
during the period September 2012 until December 2013, had a lower median post-marketing drug 
age (12.3 years), than other drugs existing on European market which did not have signals in the 
same period (19.7 years). However, it is not just the most recently marketed drugs that have safety 
signals: 58% of drugs with a signal discussed at PRAC had been marketed for more than 10 years, 
(range: 0.54–67.9), showing well-establish drugs might also generate signals. 
Apart from drug age on the market, we explored other predictors for the frequency of safety signals 
in Chapter 6.1. ATC class Antineoplastic and immunomodulation drugs, drugs dedicated for acute 
treatment and non-biological drugs had a higher risk of safety issues post-approval. We found that 
the amount of pre-approval exposure time was not associated with the risk of detecting new safety 
issues. The opposite was true for the post-approval exposure. Drugs with higher post-approval 
exposure; namely more than 1,000 patient-years of cumulative exposure in the first two years on 
the market had a 2.4 fold increase in risk of having a new safety issue compared to drugs with less 
exposure in the same period. After a certain exposure threshold (approximated at 10,000 patient-
years), the risk reaches a plateau and then decreases. 
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In order to inform regulators which criteria to consider when prioritizing safety signals, we reviewed 
different triage criteria (Chapter 5.1). We identified 48 different prioritisation criteria, which can be 
broadly categorized into four groups: novelty, public health impact, strength of evidence and public 
and media attention. More than half of the criteria (63%), referred to strength of evidence while 19% 
related to public health impact, 14% to general public and media attention and 4% to novelty of the 
drug event association. Fifteen criteria were tested for predictive value (e.g., they can predict true 
signals) with 11 showing positive results, most of them from the strength of evidence category. The 
multi-national reporting, quality and completeness of reports had predictive value. In contrast, the 
reporter qualification variable (whether the reporter is medically vs. non-medically qualified) was not 
associated with true signals. Six decision making frameworks were found in the literature, five of the 
frameworks were tested for validity and showed usefulness, while at least three are already in use for 
prioritization in various organizations. 
Chapter 7 contains a general discussion about the implications of the findings from this thesis, as 
well as recommendations for current regulatory practice and future research. 
GENERAL DISCUSSION
Regulatory decision making and science
The decisions of regulatory agencies should be grounded in science. Regulatory science, a newly 
emerging field, is ‘the science of developing and validating new standards and tools to evaluate and 
assess the benefits and risks of medicinal products, facilitating sound and transparent decision making’.
[4] In an Editorial from 2011, the FDA commissioner stressed that it is vital for regulators to develop 
new tools, standards and approaches that efficiently and consistently assess the safety, efficacy and 
performance of products, and that this field has long been overlooked and underfunded. [5] 
Regulatory decision making is a fragile balance between two choices that are not always easy to 
reconcile [6] and often need to be done in a realm of uncertainty due to limited data. The first 
choice is protection of public health, by approving only drugs whose benefits outweigh the risks 
and the other choice is to ensure timely access to therapeutic innovations for patients in need. The 
information available before a medicine is authorised is limited and ‘real-world’ use has an important 
contribution to the knowledge of the drug safety profile [7]. As Stricker and Psaty put it in an early 
editorial, ‘widespread marketing of a new drug is, in fact, a large experiment on a population’ [7].
Reflecting the need for a life time approach to monitor the benefit-risk profile of a drug, the Institute 
of Medicine in the USA states ‘The approval decision does not represent a singular moment of clarity 
about the risks and benefits associated with preapproval clinical trials do not obviate continuing formal 
evaluations after approval’ [2]. 
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The safety related drug withdrawals in the last decades have reiterated the importance of a life-
time approach to safety surveillance [8] (see Table 1). An example of a more flexible approach that 
is aligned with the need to monitor the effects over the entire drug lifetime is adaptive licensing 
a ‘prospectively planned, flexible approach to regulation of drugs and biologics’ [9]. Adaptive licensing 
involves iterative phases of evidence gathering followed by regulatory evaluation and a drug-tailored 
approval [9]. Basically, by using adaptive licensing, the existence of uncertainty is acknowledged, and 
certain decisions can be postponed until more evidence is available. Not only regulators, but also 
patients, pharmaceutical industry and reimbursement bodies must balance uncertainties about the 
benefits and risks of drugs, each from their own perspective, while considering alternative treatment 
opportunities [10].
This thesis aimed to generate data tto support evidence-based decision making. As mentioned 
already in the introduction, we classified the areas in signal management addressed in this thesis in 
three categories: data sources, methods of detection and prioritisation process.
Data sources for signal management: spontaneous reports vs. electronic health 
care records 
In this thesis we investigated different sources for signal detection: spontaneous reports and EHRs. 
Spontaneous reports are important for detection of safety signals post-marketing and they are, in 
many cases, the only source of evidence [11]. Spontaneous reports are efficient in identifying rare 
serious adverse events in a population. An example given by Stricker in a 2007 editorial is that in a 
country as UK, with 60 million people, a 1% cumulative exposure to a drug will lead to 600.000 people 
being exposed; even a rare event, with an incidence of 1:10 000 might be spontaneously reported 
and detected and in this case, especially if is recognized as drug-induced [7]. To identify such rare 
events in EHRs systems, very large populations (several hundred thousand or even several million 
people) and long follow up times would be needed [2]. Despite the efficiency of SRSs, there are 
many limitations to their use, as described in the Introduction. Not all events are equally detectable 
in SRSs, some of them might be more effectively monitored by using other data sources [12]. The rise 
of safety related warnings and product withdrawals as the notorious rofecoxib, led to investigation 
of alternative data sources for signal detection. It was suggested in the Institute of Medicine that 
alternative data sources such as EHRs might be used for detecting signals more rapidly [2].
Although initially not specifically designed for research, EHRs are used, beyond their primary 
administrative and clinical aim, for observational studies in the post-marketing setting. EHRs, 
either medical records or claims databases, have been evaluated as sources for signal detection 
and evaluation. Compared to spontaneous reports, these data sources provide a proper population 
and exposure base, more clinical information and have a longitudinal dimension [13]. The current 
advances in information technology offer the potential to access and integrate these data and 
generate evidence in a timely and meaningful way. Although they are widely used already for 
hypothesis testing, therefore for signal evaluation and assessment, the use of EHRs in signal detection 
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is still in its infancy. The potential utility of EHR for complementing signal detection was tested by 
multiple research groups during 2008-2016 [13–15] with different results.
The Observational Medical Outcomes Partnership (OMOP) project aimed to evaluate the 
performance of various analytical methods for signal detection, using a common data model on 
different data sources in the USA. With the aid of a specific reference set, the OMOP team evaluated a 
range of detection methods in different EHR databases [14]. They found that by holding the analysis 
constant, different data sources may yield different estimates. The opposite was also true by holding 
database constant, different analytic design choices may yield different estimates. A third finding 
was that the methods have quite a broad empirical performance, which can be improved with 
proper calibration [14]. The EU-ADR project tested 10 different signal detection methods in EU-ADR, 
an EHR network comprising over 20 million subjects from 7 databases across 3 European countries. 
A reference standard of known ADRs was used to test the performance of the methods. The highest 
performance was achieved by either longitudinal gamma poisson shrinker (LGPS) or case-control. 
[16] In addition, a method for removal of protopathic bias was tested – longitudinal evaluation of 
observational profiles of adverse events related to drugs (LEOPARD). LEOPARD increased the overall 
performance, but also flagged several known ADRs as caused by protopathic bias [16].
Trifiro et al. compared signal detection performed in the EHR datasets in EU-ADR with two 
spontaneous reporting databases (FAERS and Vigibase) [17]. They focused on six events of 
interest (bullous eruptions, acute renal failure, acute myocardial infarction, anaphylactic shock, 
rhabdomyolysis, and upper gastrointestinal bleeding) and concluded that the performance of signal 
detection in both EHR and SRSs varies across events. A similar conclusion was reached by Harpaz et 
al who compared the FAERS and OMOP [18], after performing a similar exercise in FAERS database. 
Harpaz et al compared MGPS, PRR, ROR and logistic regression. AUC was used as a performance 
metric. Examination of AUCs by event reveals that the methods applied in FAERS are most effective 
in identifying ADEs relating to gastrointestinal bleeding and acute renal failure, and least effective 
in signalling ADEs relating to acute myocardial infarction. For the outcome of myocardial infarction, 
detection in the OMOP network of claims databases had better performance. 
The PROTECT initiative in Europe also explored signal detection methods tailored to EHRs [19], 
as described in the Introduction. Their applied method (temporal pattern discovery) was more 
conservative (more specific, less sensitive) identifying a lower number of drug-adverse event pairs 
than the reference method [20].
In our comparison of signal detection in EU-ADR versus EudraVigilance across five events of 
interest: bullous eruption, acute pancreatitis, upper gastrointestinal bleeding, hip fracture and 
acute myocardial infarction, we found out that the capacity of EU-ADR and EudraVigilance to 
detect signals differs depending on the nature and background incidence of the ADR investigated. 
EudraVigilance performed well in case of rare events such as bullous eruption and acute pancreatitis. 
This might not be unexpected since spontaneous reporting systems were specifically constructed 
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for efficient safety monitoring, while for EHR this is a secondary use. Additional explanations are the 
lower catchment population for EU-ADR compared to Eudravigilance (almost 10 times lower) and 
the fact that EudraVigilance has a worldwide coverage, whereas the source population in EU-ADR 
covers only 30 million persons. The EU-ADR network was most useful in identifying multi-factorial 
and more frequent events such as hip fractures. Hip fracture is multifactorial and occurs relatively 
common in the population, with an incidence around 117/100,000 person years [21]. These factors 
(common occurrence and multi-factorial aetiology) might contribute to a decreased recognition 
of the event as being an ADR and therefore to a decreased spontaneous reporting. Consequently, 
this type of events will not be easily recognized as drug-induced and therefore not reported. An 
illustration of this was the lack of recognition of the myocardial infarction associated with rofecoxib 
(see Introduction). Both systems detected gastrointestinal bleeding reasonably well and myocardial 
infarction rather poorly. If we extrapolate the findings, this means that there is a correlation between 
the background incidence of the ADRs and the capacity of each database to generate signals. We 
tested this and the correlation was statistically significant for EudraVigilance, but not for EU-ADR, 
which may be due to the low number of events tested. Applicability of our findings to a broader 
range of events requires further investigation. If this finding is reproduced, it might serve as a basis 
for tailored made signal detection: spontaneous reporting systems will be used only for certain 
events, and complemented by EHRs for the others. 
Signal detection methods 
Given the existing data source, another important question in signal detection is how we can 
improve the performance of detection methods by simultaneously increasing sensitivity and 
specificity. Especially in the area of paediatrics improvement of signal detection methods has been 
lagging behind, as initially children were not looked at separately [22]. Paediatric patients may differ 
from adults regarding the pattern of drug use and ADRs occurrence [22-24]. Applying the same 
methods as for the adult population may lead to masking of signals [25,26].
We investigated the impact of age on signal detection methods in paediatrics. Stratification is the 
correct method to inspect confounding and/or effect-measure modification across various strata 
[27]. Through stratification we create categories in which the confounding factor does not vary or 
varies very slightly. Afterwards, there are two ways to summarize information across strata- either 
by reporting the estimate in each stratum (subgrouping or stratification) or reporting an adjusted 
overall estimate (adjustment) [27]. Effect modification differs from confounding in several ways: 
whereas confounding is a bias that needs to be identified and removed from the effect estimate, 
effect modification is based on biology (e.g, higher or less susceptibility by age due to differences 
in organ maturation) and should be observed and described but not adjusted [27]. Our study in 
paediatrics showed that adjustment for age decreases overall the performance of signal detection, 
both in sensitivity and specificity. On the other hand, stratification by age led to unmasking of new 
signals in certain age categories. This supports the hypothesis that beyond a confounder, age may 
be an effect modifier in signal detection in children. 
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Our finding was in line with that of Seabroke et al. [28], who also found that age-subgroup analysis 
performs better than crude analysis in both sensitivity and precision. Other studies have also found 
that stratification may perform better than adjustment [25,29]. In one study conducted within 
the PROTECT consortium, signal detection performance (evaluated by sensitivity and precision) 
was compared for stratified, subgroup and unadjusted analyses within five spontaneous report 
databases (VigiBase, EudraVigilance, UK regulatory agency database, GlaxoSmithKline’s and Astra 
Zeneca’s safety databases). Analyses were repeated for a range of covariates: age, sex, country/
region of origin, calendar time period, event seriousness, vaccine/non-vaccine, reporter qualification 
and report source. The most relevant variables were age and region/country of origin [28]. Subgroup 
analysis performed better than crude analysis in both sensitivity and precision, while stratified analysis 
did not. Subgrouping by type of drug (vaccines/non-vaccines) led to mixed results: it has resulted 
in a decrease in both precision and sensitivity [28]. One study performed on a large international 
spontaneous reports database (Vigibase), found that vaccines have a large and mathematically 
predictable impact on signal detection in the paediatric population [29]. Another study performed 
on a smaller company-owned vaccine-specific database [30] found a rather modest masking effect. 
In conclusion, with regards to vaccines stratification, the evidence is mixed. 
The risk of over-stratification if too many variables are adjusted for was highlighted by Hopstadius 
et al. [31] in a simulation study performed in the WHO database where they compared crude and 
adjusted signal detection methods based on random allocation of reports to a set of strata with a 
realistic distribution of stratum sizes. The study demonstrated that adjustment led to underestimation 
of effects relative to the crude analysis, in the presence of very small strata. If strata are large enough, 
this tendency can be avoided and stratification might be useful. 
Based on our results, and the sum of existing evidence, we conclude that routine use of age 
adjustment in paediatric signal detection is not recommended while stratification can be used on 
top of unadjusted analysis, to avoid masking of signals.
Drug utilisation data and its role in pharmacovigilance
Drug utilisation data are an important aspect for pharmacovigilance as clinical trials have limitations 
with regards to safety in terms of patient exposure and length of follow-up [32]. Knowledge of how 
a drug is used in real life in terms of actual usage, dosages, polypharmacy, helps estimating the 
absolute risks and public health impact and also informs risk minimisation strategies.
A study which investigated medicines approved between 2000 and 2010 found that the median total 
number of patients studied before approval was 1,708 ([IQR] 968-3,195) for standard medicines and 
438 (IQR 132-915) for orphan medicines [32]. In addition, the same study found that for medicines 
intended for chronic use, the number of patients studied before marketing is insufficient [32]. The 
study concluded that both safety and efficacy require continued study after approval. 
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At the moment, information about drug exposure post-marketing is not very easy to collect, especially 
when multiple countries or regions are involved. Firstly, drug utilisation data can be collected 
at different points in the drug use chain: sales from manufacturers, dispensing, prescription or 
reimbursement. Secondly, the data might be collected by different parties: governmental agencies, 
insurance companies or pharmacies and can be recorded in different units. The PROTECT project, 
started to address this problem by building an inventory on drug consumption databases across 
Europe, which was finalized in February 2015 and serve as a comprehensive source of information 
[33].
Drugs differ quite a lot in terms of drug exposure, both qualitatively and quantitatively. This depends 
on indication(s), patterns of use and healthcare policies in the countries where those drugs are 
marketed. We showed that for drugs with a very rapid market uptake (e.g. more than 1,000 patient-
years of exposure in the first two years after approval), we detect more new safety issues in this 
period. This doesn’t necessarily mean the drugs are intrinsically riskier but rather that they reach 
faster a sample size large enough to allow identification of signals. It was also observed that after a 
certain exposure threshold, the chance of detecting a new ADR, decreases. We approximated this 
threshold to be around 10,000 patient-years. Since it was an exploratory categorical analysis, this 
finding should be reproduced by other researchers in different settings. Although this finding is not 
consistent with statistical reasoning, which states that more exposure should lead to more power 
and more issues detected, it may be considered a ‘saturation’ phenomenon; after most of the ADRs 
are known, less and less new ADRs will be reported and discovered. Additional explanations for this 
phenomenon could be better risk management; medical professionals becoming familiar with the 
product and decreased reporting. Our finding is in contrast to the one of Mol et al. [34] who found 
that the level of use in clinical practice does not affect the number of post-approval safety issues. 
Several methodological differences might have accounted for that: Mol et al selected only innovative 
drugs (in contrast to all new drugs in our case) and only hospital based Dutch exposure data was 
used (while we used worldwide sales data). Furthermore, they adjusted for different confounders 
and the study period was different. 
In contrast to post-authorisation exposure, the amount of pre-authorisation exposure did not seem 
to influence the number of detected signals in our study, at least during the initial years on the 
market. Another study had a similar finding [35] while Mol et al found the opposite: a larger pre-
approval study population led to an increased risk of a serious safety issue [34]. 
Our studies did not focus on the qualitative aspect of drug exposure: not only does the number of 
patients exposed change post-approval, but, more importantly, the type of patients may change. 
A literature review which compared RCTs population in the fields of cardiology, mental health, and 
oncology, with real-world populations for which the drugs were indicated, demonstrated that the 
real-world populations are very different from RCTs in terms of demographics, clinical characteristics 
and polypharmacy, up to the point where they might jeopardize the external validity of RCTs [36].
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However it is different to study the impact of these changes on a global scale, since aggregated high 
level sales data often do not reveal these details. 
In view of our findings on pre- and post-marketing exposure time regarding new safety issues, we 
recommend that drug exposure data are considered when planning the drug surveillance process, 
and particular attention should be given to drugs with a steep increase in exposure early after 
marketing. Also considering the conflictual findings existing in literature, more research in this area 
is needed. It appears that drug exposure is a variable that is correlated with drug safety and it was 
neglected over the last years. 
Where to focus in signal detection; the need to prioritise
With the constant addition of data sources and automatization of the signal detection, there is a 
legitimate concern that the number of generated signals might surpass the current capacity for 
analysis [37]. Therefore, is important that signals are prioritised during the entire signal management 
process. The real challenge in drug surveillance is to detect serious ADRs as early as possible, before 
too many patients are exposed to harm. There are multiple factors that may influence occurrence of 
ADRs: the drugs’ pharmacological and toxicological profile, the patterns of drug use, the population 
for which the drug is indicated, time on the market and prescriber and consumers’ experience with 
it [38].
Novelty 
In Chapter 2.1 we have shown that while most signals are identified for recently approved drugs 
also older drugs [39] still have new safety issues. Novel drugs being more likely to have safety signals 
is not a surprising, nor a new finding. A study from the US which included drugs approved between 
1975-2000, found that new drugs have a higher likelihood to have safety issues (defined as ‘black 
box warnings’ and drug withdrawals). Half of ‘black box warnings’ occurred in the first 7 years of drug 
introduction and half of withdrawals occurred in the first 2 years [40]. Although the famous ‘Weber 
effect’ [41] (i.e., adverse events reporting peaks at the end of the second year after approval) was 
not reproduced in recent studies [42,43], there are studies which showed that novelty influences 
the risk of finding new safety issues [44,45]. Since we used age as a continuous variable, we cannot 
recommend a threshold for separating drugs into ‘old’ vs. ‘new’. Other studies proposed a threshold 
of two and respectively five years for this classification. In conclusion, ‘novelty’ in regulatory and risk 
management field equates more uncertainty and therefore higher risk, leading to higher priority. 
The fact that more than half of drugs with a signal discussed at PRAC have been marketed for 
more than 10 years might seem counter-intuitive. Still, the signals identified for well-established 
drugs might be explained by several factors such as: change in drug utilisation patterns, change in 
morbidity of underlying population or increased awareness about ADRs. An illustrative example is 
the one of codeine and life-threatening toxicity through overdose in CYP
2D6
 ultra-rapid metabolizers, 
[46] a signal discovered only recently, despite the fact that codeine has been used for more than 
50 years. Codeine is a prodrug and needs to be converted to morphine by the cytochrome P-450 
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isoenzyme 2D6 (CYP
2D6
); which later is inactivated through glucuronidation. Patients with a normal 
range of CYP
2D6
 activity represent 75-92% of the population, while 5-10% are ultra-rapid metabolizers, 
who can quickly convert codeine into large amounts of morphine. In children, the rapid conversion 
of codeine into morphine can be dangerous since the glucuronidation systems are immature and 
morphine inactivation is slower. In April 2012, a case series was published reporting two deaths and 
one case of respiratory depression in children 3 to 5 years of age who had received typical doses 
of codeine after tonsillectomy or adenoidectomy. In response to these cases, regulators in Europe 
and US started an evaluation of the safety of codeine in children and identified even more cases of 
morphine overdose. The regulatory actions included a ‘black box warning’ in US and restriction of 
codeine use in paediatric patients both in US and Europe. This case illustrates not only the value of 
anecdotal reports in pharmacovigilance but also the need for continuous monitoring during the 
entire lifetime of a product. In paediatrics, such surprises may occur with older drugs, as for their 
licensure, children were not included in clinical trials, a rule which now has been changed, with the 
updated paediatric legislation from 2007 [47]. 
Strength of evidence 
The findings that the multi-national reporting (or geographic spread) has predictive value for true 
signals [44,48] needs to be emphasized more. EMA recently changed its practice based on new 
results [15] and now considers subgrouping by country or continent of origin in its signal detection 
practice. WHO also applies it in VigiBase [49] with promising results. Overall it highlights the need to 
create networks of multinational collaborations to augment signal detection. 
Using the information on quality and completeness of spontaneous reports during prioritisation 
phase, seems to be useful as well, as Caster et al demonstrated during testing of Vigirank system [48]. 
Vigirank was designed as a data-driven screening algorithm for drug safety signals that accounts or 
report quality and content [48]. For the quality of the reports, two parameters were included: reports 
were scored on completeness (if they contain sufficient information to allow a causality assessment) 
and number of reports with free text narrative available were counted. Using Vigirank led to a 
statistically significant improvement in detection performance, assessed by AUC and compared with 
the classical disproportionality method and with raw number of reports. In a new study, involving real 
world use in WHO database, VigiRank significantly outperformed disproportionality analysis alone in 
signal detection [49]. Surprisingly, the reporter qualification (medical vs. non-medical) failed to show 
predictive value for signals [45]. This is interesting to note since, before the legislative changes in 
2012, medically confirmed reports were perceived as being of higher quality and were prioritized in 
the reporting process (expedited reporting to authorities) as well as in signal detection procedures 
[50], which use to give less weight to patient reports. Although the USA, have given patients the 
possibility to report since the start of their pharmacovigilance systems, in Europe the role of patients 
as a source of ADRs has not been fully accepted until recently [51]. The Netherlands and Sweden 
were among the first countries to implement patient reporting and now this is an integral part of 
the SRS all over EU. there is evidence that reporting by patients can be an important complement 
to the reporting by healthcare professionals [52]. Examples of signals where consumer reports have 
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been of crucial importance for signal detection are electric shock-like sensations associated with 
the use of duloxetine, and persistent sexual dysfunction after discontinuation of selective serotonin 
reuptake [51].
Public health impact 
The public health impact is the impact of the ADR at population level, expressed through the 
number of patients affected by an ADR and its consequences [53]. Variables related to public health 
impact are: the seriousness of the event, fatality rate or potential for serious consequences, size 
of the population with the target disease and size of the treated population, potential to affect 
vulnerable populations and potential for prevention. More recently, the individual health impact 
is also taken into account both by FDA and EMA authorities. FDA estimates the hazard posed by 
a significant safety issue, based on three variables: (1) the relative seriousness of the issue; (2) the 
estimated size of the population exposed to the risk of the drug; and (3) the suspected frequency 
of harm to patients exposed to the drug. The combination of factors 2 and 3 provides an estimate 
of population risk; the combination of factors 1 and 3 provides an estimate of personal risk to the 
patient [54]. Similarly, in Europe, in the newly updated guidance on signal management [55] both 
individual and public health impact are separately mentioned. When the public health impact is 
very high, it can even take precedence over strength of evidence, and regulatory actions can be 
taken before definitive evidence is gathered [53]. We illustrate this with examples related to two 
intensely mediatized signals; adjuvanted influenza A(H1N1) vaccine and narcolepsy and tiotropium 
and cardiovascular side-effects. 
A safety signal around Pandemrix®, an adjuvanted influenza A (H1N1) vaccine was identified 
in August 2010, suggesting that the vaccine causes narcolepsy in children and adolescents. The 
signal originated from Finland and Sweden, two countries with very high vaccine coverage rate in 
the entire population (60-70%) [56]. The issue received extensive media attention and the Nordic 
countries as well as other EU countries conducted rapid risk assessment studies to substantiate 
the signal [57]. The results differed across countries and the biological mechanism is still unclear to 
date. At the same time, the extensive media awareness and public unrest urged for regulatory and 
political actions; an EU referral procedure, product information update, restriction of indication in 
children and compensation of the victims occurred. A global research project (SOMNIA) was set 
up to study this and demonstrated that the effects of adjuvanted pdm A (H1N1) vaccines were not 
observed in other countries [58]. 
Another example of a signal with a high public health impact is the increased rate of death 
associated with soft-mist Respimat® inhaler. Respimat® inhaler is a new formulation of the active 
substance tiotropium aimed to increase bioavailability and efficacy. A risk of increased mortality 
from cardiovascular disease and all-cause mortality in association with tiotropium Respimat® was 
identified from a large meta-analysis, back in 2008 [59]. The signal was analysed by the European 
Pharmacovigilance Working Party which decided to update the product information to reflect the 
increased mortality. In 2012, an editorial in the BMJ journal called for drug withdrawal based on the 
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current evidence [60]. The signal was re-discussed at EU level, the evidence was carefully assessed, 
and it was concluded that all the evidence presented in the editorial was already considered in 
the previous evaluation. Consequently, the previous conclusion was considered valid and it was 
decided to wait until the finalization of an ongoing large clinical trial, which could offer more insight. 
Meanwhile, a case-control study finalised in 2012 [61] identified an 27% increased risk in overall 
mortality and cardiovascular death. The authors stated that is unclear if this association is causal or 
due to residual confounding. In 2013, the awaited RCT (involving more than 17,000 patients with 
COPD for a median duration of 835 days), TIOSPIR trial [62] found no difference in the overall or 
cardiovascular mortality between tiotropium Respimat® and Handihaler® (the original formulation) 
in patients with and without baseline cardiac disorders. In view of these new results, the signal 
was reopened and discussed at PRAC. It was decided that no action is needed besides an update 
of product information to fully reflect the study results. Considering the high prevalence of COPD 
(7,6%, in Europe) [63], the widespread use of the drug, recommended as first line treatment and the 
most prescribed COPD treatment worldwide, summing more than 31 million patient-years of use 
[64] and the severity of side effects, the public health impact of this issue was considered to be very 
high. Therefore, the signal had top priority for evaluation and re-opened each time new evidence 
was available.
Although not as important as the strength of evidence, the factors related to public or media 
attention are important to consider, to prevent panic and unintended consequences as switching 
therapies or abrupt interruption of treatment.
Signal validation–a case study
Once a signal of a potential drug safety issue is identified, signal validation and evaluation have 
to follow rapidly to confirm or refute the association and to describe it in terms of frequency, 
seriousness and additional risk factors. In Chapter 3.2, we performed a signal validation through 
a pharmacoepidemiological study. We evaluated the association between triptans and ischemic 
colitis, by using a nested case-control study design in a primary care database from the UK (THIN). 
This association is another example where the precautionary approach took precedence over 
strength of evidence. Based on a few well-documented case reports, regulators decided to update 
the product information of triptans with the adverse event of ischemic colitis. At the moment the 
association was not confirmed in any hypothesis-testing study. The only evidence existing in the 
literature came from a case control study performed in an US claims database (Kaiser Permanente 
Medical Care Plan) [13], which included a very limited number of triptans users (n=16) and did not 
find an association between triptans use and ischemic colitis. More evidence was needed. We found 
an increased risk of ischemic colitis associated with triptans’ treatment. The most important study 
limitation was the lack of power which led to borderline significant results and restricted us to 
further investigate exposure windows. We think the finding should be replicated in a more powered 
study, ideally a multi-national one. 
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Methodological considerations of the research contained in this thesis
The challenge of an evaluation exercise in absence of optimal reference standards 
Before embarking on a mission to change the current practice of signal management we need 
to know what the actual performance is. The usual method used to assess performance of signal 
detection algorithms is by using diagnostic test-related parameters [65] as sensitivity, specificity, 
positive predictive value and negative predictive value or AUC. These metrics assess the algorithms’ 
capacity to discriminate between true signals and non-causal associations. To be able to use these 
metrics we need a reference standard for comparison, composed of ‘true positive’ and ‘true negative’ 
signals, classified according to the best currently available evidence. The sources of evidence for 
true drug-disease associations may be: published scientific literature, product information leaflets 
or expert opinion.
The absence of a robust reference standard represents a major obstacle in evaluating the performance 
of signal detection methods. Even when they do exist, reference standards are mostly sub-optimal. 
Firstly, most reference standards are limited in size, due to time-constraints. They contain a limited 
number of drug event-associations and it is customary to focus on a small set of drugs or outcomes 
of interest. This is also the case for our paediatric reference standard used in Chapter 4.1, which 
focuses on of 16 paediatric drugs and 16 ADRs. Secondly, many reference standards also lack verified 
true negatives (controls), and their focus is on positive test cases only. This is a major limitation 
since in absence of true negative associations we cannot assess specificity of the method or the 
AUC. Only a partial performance can be calculated. We have avoided this in our research by using 
only reference standards with both positive and negative cases. A third limitation, which is also 
very difficult to avoid, is the possible correlation between the constructed reference standard and 
the database where the method is applied. Even if not directly consulted in the creation of the 
reference standard, information from spontaneous reporting often contributes to product labelling 
and the patients’ perception of ADRs and might influence the classification [66]. We could not avoid 
this completely in either since we used information from product information leaflets for verifying 
the true positive signals. Information contained in product information leaflets might influence the 
reporting behaviour. 
Ultimately, constructing a universally valid reference standard to test signal detection methods 
for challenging since causality assessment is not a black and white decision and is also fluctuating 
with time. Knowledge accrues over time as supplementary data like new studies, better conducted 
and in larger populations substantiated with biological evidence, or simply more cases become 
available. This is one reason why many research groups construct their own reference standards at 
the time of the study. The most common approach has been to use historical (‘time-frozen’) safety 
signals as positive controls. However, as mentioned before, the signals might change over time and 
therefore lead to misclassification. Noren et al. [67] argue that evaluation should be done against 
emerging and not established adverse events, and a time stamped reference database of ADRs 
would be the best way forward. 
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Earlier efforts to develop reference standards were usually not systematic or transparent about 
their decision process, were limited in the size and diversity of drug-outcome pairs included, or 
lacked negative controls. This eventually got better as various research groups attempted to create 
reference standards for the purpose of testing signal detection methods:
EU-ADR reference standard was based on existing scientific literature and expert opinion and 
included 44 positive associations and 50 negative controls for the ten outcomes of interest: bullous 
eruptions; acute renal failure; anaphylactic shock; acute myocardial infarction; rhabdomyolysis; 
aplastic anaemia/pancytopenia; neutropenia/agranulocytosis; cardiac valve fibrosis; acute liver 
injury; and upper gastrointestinal bleeding [68]. PROTECT reference standard was compiled based 
on information contained in the product information of 220 drugs approved in Europe [15]. Date 
when the ADR appeared in product information is also captured. It contains only positive test cases. 
Harpaz et al. constructed a reference set based on drug labelling revisions, such as new warnings, 
which were issued and communicated by the US Food and Drug Administration in 2013. The 
reference standard includes 44 drugs and 38 events, both positive and negative cases and is time 
indexed, containing the date when an association (positive test case) became known according to 
product labels [66].
For the purpose of methods testing OMOP built a reference set of 399 test cases: 165 ‘positive controls’ 
that represent medical product exposures for which there is evidence to suspect an association with 
the outcome, and 234 ‘negative controls’ that are drugs for which there is no evidence that they 
are associated with the outcome, for four health outcomes of interest: acute myocardial infarction, 
acute liver injury, acute renal failure, and gastrointestinal bleeding. The reference standard spans 
181 unique drugs, including nonsteroidal anti-inflammatory drugs, antibiotics, antidepressants, 
angiotensin-converting enzyme inhibitors, β-blockers, antiepileptics, and glucose-lowering drugs.
The work is continued by OhDSI who tries to develop an impressive reference set of 1,000 active 
ingredients across 100 HOIs [69]. They want to capitalize on previusly contructed reference sets 
and use a wide range of information sources as: literature, product information and observational 
healthcare data. 
Since none of the existing reference standards was fit for purpose (being restricted either in number 
of products or outcomes covered), in this thesis we used two reference standards tailored to our 
research. One was constructed based on published scientific literature and expert opinion (Chapter 
3.1) and consists of both positive and negative reference drug events pairs, focused on selected 
outcomes of interest. We included both positive and negative controls, and scientific literature was 
used as source of information. In contrast to the approach used in previous studies, verification was 
performed for all drug-event associations associated with the events of interest, irrespective if they 
were highlighted as signals or not. 
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The second reference set used in Chapter 4.1 was paediatric-specific and based on evidence 
from product information and the published literature. This is also a new addition in the research 
community, being the first paediatric specific reference set. This one is smaller in size, a combination 
of 16 paediatric drugs and 16 ADRs of interest for paediatric population, which resulted in 37 positive 
and 90 negative controls [70]. 
Statistical Power
Another problem frequently encountered in either signal detection or evaluation when we usually 
deal with rare events is lack of sufficient power. We encountered this in Chapter 3.2 when trying to 
investigate the association between triptans and ischemic colitis. In signal detection, the overall size 
of a database is not the main determinant of the statistical power but rather the drug exposure data 
[71,72]. Coloma and colleagues estimated for which type of drugs we have enough power to detect 
signals in a network of European EHR databases, EU-ADR [72]. Their findings showed that combining 
EHRs for active drug safety surveillance does increase power, but it may still be not high enough for 
rare and very rare events and for drugs that are infrequently used. Multi-national and multi-database 
networks that offer access to large and heterogeneous populations might be of help. 
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CONCLUSION AND FUTURE PERSPECTIVES 
The motivation behind exploring signal detection and evaluation processes is the timely detection 
of safety issues, and ultimately a better protection of public health. This thesis aimed and to provide 
informative evidence for regulatory decision making in the areas of signal detection and evaluation. 
In terms of additional data sources, we explored the use of EHRs, which proved to be challenging 
but their use might have added value for detection, especially in assessing frequent events or events 
which are not likely to be recognized as ADRs.
There is a shift lately in pharmacovigilance towards an increased usage of real-world data. Large 
networks of EHRs increase heterogeneity and size of available populations for analysis of drug 
safety, at a level that cannot be attained by individual databases alone [73]. The problem in Europe 
is that these resources are fragmented and highly heterogeneous in terms of structure, coding, and 
content. The heterogeneity problem can be addressed in different ways, summarized below.
Multi-database and multi-centre studies are essential for increasing power and generalizability of 
the results and several initiatives started in parallel in US, Canada and Europe to support them. Many 
of current studies use data from multi-database or multi-national networks. Some of these networks 
were formed ad-hoc for a particular study while other are more permanent/broad in scope and can 
be reused for different studies [74]. In Europe, multinational studies were further supported since 
2007 through public and public/private EC initiatives such as the European Commission’s Seventh 
Framework Programme (FP7) [73], Horizon 2020 [75] programmes and the Innovative Medicines 
Initiative (IMI) [76].
Examples of networks created to support multi-database and multi-national studies are ENCePP [13] 
which is network of centres and all the project based networks in Europe (e.g. EU-ADR, SOS, ARITMO, 
SAFEGUARD, CARING, PROTECT, VAESCO, ADVANCE, EMIF). Successful examples of multi-databases 
networks used in regulatory agencies are Sentinel and Canadian Network for Observational Drug 
Effect Studies (CNODES), both distributed data networks [77,78]. Sentinel is a FDA mandated 
and highly funded distributed data network that allows secure access and analysis of very large 
populations (more than 223 million members as of September 2017) [77]. In Canada, CNODES is 
a multi-provincial distributed network funded by Health Canada which started in 2011. An even 
more ambitious project, OMOP created a common data model that was implemented in over 50 
databases, leading to a truly global network [79]. The work is now continued by OhDSI, whose focus 
is on the development of open source solutions for observational data [79]. (see a more complete 
description of these in Chapter 1).
In Europe, the ENCePP network focuses on gathering expertise and increase collaboration and does 
not have databases in-house. It has a Working Group dedicated to the initiation and conduct of 
observational research using multiple data sources and to develop guidance on conceptual models 
for multi-national and multi-database studies [80].
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There are several methods to conduct multi-database or multi-national studies, ranging from less 
to more centralized [74,81], illustrated in Table 2. The traditional’ and well accepted approach way 
of integrating results from different databases was by meta-analysis of results of individual studies 
designed by the local investigators. It requires no collaboration, however the lack of harmonization 
of study design makes heterogeneity of the results hard to attribute either to methodological or 
clinical heterogeneity [82,83]. The newest approaches are: 
• Common protocol, local data management and analysis. 
Data are extracted and analysed locally on the basis of a common protocol. Definitions 
of exposure, outcomes and covariates, analytical programs and reporting formats are all 
standardised. Analyses are conducted locally and afterwards, the estimates are pooled together. 
This model ensures more harmonization of study design, and removes some potential sources 
of variability. It is a distributed approach where data partners maintain physical and operational 
control over electronic data in their existing environment. This approach was employed by 
PROTECT project [19], and TEDDY project in paediatrics [84]. Outside Europe, the Canadian 
Network for Observational Drug Effect Studies (CNODES) a multi-provincial distributed network 
started in 2011, is another successful example [78]. Similar to Sentinel, data are extracted and 
analysed locally and afterwards combined in a summary estimate [78]. 
• Common protocol, project specific common data model and common analytics
In this distributed model study-specific data are extracted locally and transformed into a 
common data model. A standardized script can then be run across all sites, which generates 
aggregated output that can be shared and pooled. This is a very successful and efficient model 
in Europe. It has been employed by many studies as EU-ADR, SOS, GRIP, ARITMO, SAFEGUARD, 
EMIF, ADVANCE and many commercial post authorisation safety studies. A characteristic of this 
model is that the creation of study variables is local and requires close collaboration with the 
data access provider. This model has been much developed an many tools have been made 
available to support it: from code mapping tools (Codemapper [85]) to standardized analytics (in 
Jerboa, SAS, R), and fit for purpose assessments [86].
• Common protocol, general common data model and common analytics
Local data are converted in a generalised full common data model which stays local, but can 
be analysed with standardized analytics. This is the most ‘general’ of all systems, which allow 
flexibility to the analysers to define study variables from different components of data in the 
common data model. Widely known examples of this approach are VSD, Sentinel, PCORnet 
and OMOP. The common data model differs between these approaches. The Sentinel common 
data model and OMOP one differ with regard to design and the availability of derived variables. 
Sentinel has the original variables and leaves it to the study to derive variables, whereas OMOP 
maps the original variables in several derived variables beforehand. 
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Table 2. Differences among the multi-databases strategies with respect to responsibility in the data 
management and analysis and expected output
Model Data 
extraction
Data 
management
Data 
analysis
Output shared 
with partners
Examples
1. Common protocol, local data 
management and analysis
Local* Local Local Final  
estimates
PROTECT
TEDDY
CNODES
2. Common protocol, project 
specific common data model  
and common analytics
Local Local, study-
specific
Central Raw data in a 
common  
data model
EU-ADR,SOS, 
GRIP, 
ARITMO, 
SAFEGUARD, 
EMIF, 
ADVANCE
3. Common protocol, general 
common data model and 
common analytics
Local Initially local,  
then central
Central Patient 
level data, 
aggregated 
data or final 
estimates
VSD, 
Sentinel, 
PCORnet, 
OMOP
PROTECT= Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium; TEDDY = 
Task-force in Europe for Drug Development for the Young; CNODES= Canadian Network for Observational Drug Effect 
Studies; EU-ADR= Exploring and Understanding adverse drug reactions; SOS= Safety of Non-Steroidal Anti-Inflammatory 
Drugs; GRIP= Global research in Paediatrics; ARITMO= Arrhythmogenic Potential of Drugs; EMIF= European Medical 
Information Framework; ADVANCE= Accelerated development of vaccine benefit-risk collaboration in Europe; VSD= 
Vaccine safety datalink; PCORnet= National Patient-Centered Clinical Research Network; OMOP= Observational Medical 
Outcomes Partnership
* ‘Local’ refers to the data custodian, ‘central’ refers to the coordinating centre of the study; 
The existence of multiple networks has transformed the way that we conduct 
pharmacoepidemiological studies and will likely continue to do so. The advantages of such 
networks, once created, are statistical power, high external validity and speed of delivery of results 
(e.g., Sentinel can deliver in days or weeks depending on the research question) [77]. What would be 
needed is such a sustainable system in the EU rather than project based networks that have a limited 
time-span and limited generalizability. 
The role of regulators and researchers –recommendations for practice and areas 
of future research
• Which data source to use: spontaneous reports vs electronic healthcare records. 
spontaneous reporting systemss are still the mainstay of pharmacovigilance and should 
continue to be screened. Their value is greater in the area of rare and very rare reactions, easily 
recognized as ADRs, where they perform the best. Electronic healthcare records might have 
additional value, for more frequent reactions and those which are hard to be identified as ADRs 
by reporters. In Europe the problems of fragmentation and lack of compatibility of data source 
as a result of the significant heterogeneity among European data sources should be solved 
before being able to use EHRs for detection. We recommend that multi-national and multi-
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database studies are encouraged by regulators and guidance, platforms and tools to facilitate 
this are built. 
• Signal detection methods- age as a confounder or effect modifier
Age appears to be an effect modifier rather than a confounder. Age adjustment was 
systematically demonstrated to decrease signal detection performance and should be avoided. 
Age stratification can increase sensitivity (especially in paediatrics) and lead to discovery of new 
signals therefore can be used complementary to standard methods. 
• Predictors for new safety issues
Newly approved drugs should be monitored with greater caution since the knowledge of 
their benefit-risk profile is still less mature. Post-approval exposure seems to be a determinant 
of safety issues, at least in the initial period on the market. Special attention during signal 
detection should be given to drugs with potential for high and rapid market uptake, at least 
until they achieve a certain exposure threshold. The exact threshold, estimated in our study at 
approximately 10,000 patient-years should be investigated in further research. Since the studies 
investigating the relation between drug exposure and frequency of safety issues have different 
results, more research in this area is recommended. 
Multi-national reporting and report quality should be considered when prioritizing signals. In 
contrast, reporter qualification should not be considered as a prioritization criteria since it was 
not proven to be associated with true signals. 
• More testing of currently available prioritization criteria and frameworks should be done, as this 
would support creation of a robust evidence-based prioritization process. 
• Drug exposure data 
Drug utilisation data have an increasingly important role in the review of benefit-risk of 
medicinal products post-marketing. Signal detection is no exception. To ensure optimal signal 
management, efforts should be made to improve collection and accessibility of drug exposure 
information, since exposure is needed to estimate the public health impact. 
CONCLUSION
In conclusion, the dynamic nature of the drug safety field, both in the scientific and in the regulatory 
aspects, drives the continuous update of existing methods and exploration of other sources for 
investigating drug safety. There is a need to create big networks of EHR, to support signal detection 
and evaluation processes, to increase access to drug utilisation data and to invest in prioritisation 
systems. 
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Dit proefschrift omvat studies die beogen vragen te beantwoorden met betrekking tot de sub-
domeinen signaal management en regulatory science: databronnen, detectie-methoden en het 
proces van prioritering. 
We begonnen dit proefschrift met een overzicht van signalen in de EU, aangezien er grootschalige 
wetswijzigingen zijn goedgekeurd in 2010 en van kracht zijn geworden in 2012. Op basis van het 
overzicht van signalen die werden besproken in de Pharmacovigilance Risk Assessment Committee 
(PRAC), concludeerden we dat de meest gebruikte databron spontane meldingen waren (72% van 
de gevallen), net als in de VS , zie Hoofdstuk 2 (1). De signalen die besproken werden, waren het 
vaakst gerelateerd aan “Huid en onderhuidse aandoeningen” (12,8%), “Zenuwstelstel aandoeningen” 
(10,4%), “Cardiale aandoeningen” en “Immuunsysteemaandoeningen” (6,4%). We zagen dat de 
gemiddelde tijd tussen het opkomen van een nieuw signaal en een beslissing van PRAC 2,5 maanden 
was, waarbij in 42,8% van de gevallen een beslissing genomen werd tijdens de eerste vergadering. 
Voor 57,2% van de signalen werd additionele informatie opgevraagd na de eerste bespreking in de 
PRAC. Er kunnen meerdere acties genomen worden na validatie van een nieuw signaal. De actie 
die het meest vaak werd genomen was een wijziging in de productinformatie (54%). Er werd niet 
vaak besloten tot het starten van een referral (9,4%) of het versturen van een Direct Healthcare 
Professional Communication (7,3%), maatregelen die voornamelijk genomen worden voor ernstige 
en urgente problemen. Echter, het besluit om over te gaan tot één van beide voorgenoemde acties 
werd wel sneller genomen (respectievelijk 1,8 maanden en 1,7 maanden).
Spontane meldingen vormen nog altijd de hoeksteen voor het opsporen van signalen, maar hun 
beperkingen zijn algemeen bekend en om deze reden is men continue op zoek naar nieuwe 
gegevensbronnen om het proces van signaaldetectie mee te verrijken. Door meerdere problemen 
omtrent de veiligheid van geneesmiddelen in het begin van de 21ste eeuw, die veel aandacht 
hebben gekregen, gaf het Institute of Medicine aan dat spontane meldingen alleen niet afdoende 
zijn. Elektronische gezondheidszorg databases (EHRs) werden toen voorgesteld als alternatieve 
gegevensbron (2). Om te achterhalen hoe EHRs spontane meldingen zouden kunnen aanvullen 
bij geneesmiddelentoezicht, hebben wij onderzoek gedaan naar Europese EHRs als bron voor het 
oppikken van signalen. In Hoofdstuk 3.1 hebben we de databases vergeleken die meededen met het 
EU-ADR project met Eudravigilance op hun vermogen om bekende associaties op te sporen. In deze 
studie waren we beter in staat bijwerkingen met zeldzame tot zeer zeldzame achtergrondincidentie 
op te sporen in databases met spontane meldingen (SRS), evenals bijwerkingen die makkelijk aan 
geneesmiddelen toe schrijven zijn, zoals blaarziekten en acute pancreatitis. Daarentegen waren er 
bijwerkingen (bijv. heupfracturen) waar EHRs tot betere resultaten leidden.
Een belangrijke overweging bij het selecteren van gegevensbronnen voor het opsporen van 
signalen is de ratio ruis-op-signaal. Het aantal vals positieve signalen in elke gegevensbron (EU-ADR 
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en Eudravigilance) is afhankelijk van zowel het type signaal als de gegevensbron. Het laagste aantal 
vals positieven vonden we voor bovenste tractus digestivus bloedingen en acute pancreatitis, het 
hoogste aantal voor blaarziekten. Het was voor alle bijwerkingen duurder om signalen te detecteren 
in EHRs dan in SRS (bijv. omdat meer vals positieven moeten worden uitgesloten). Concluderend, 
een systeem gebaseerd op EHRs kan van toegevoegde waarde zijn voor signaaldetectie mits 
gebruikt naast de huidige systemen, vooral voor bijwerkingen met een hoge achtergrondincidentie. 
Op het moment lijken SRS meer kosteneffectief te zijn dan EHRs.
In Hoofdstuk 3.2 hebben we het gebruik van EHRs voor evaluatie van signalen beschreven 
door onderzoek te doen naar de associatie van triptanen en ischemische colitis. Vanwege de 
zeldzaamheid van de uitkomst, zijn er tot nu toe maar een handvol meldingen geweest. In de 
THIN database, die eerstelijnszorggegevens van ongeveer 6% van de bevolking van het Verenigd 
Koninkrijk bevat, konden we maar 41 nieuwe gevallen van ischemische colitis identificeren in een 
cohort van ongeveer 300,000 migraine patiënten. Het gebruik van triptanen in de 12 maanden voor 
het event verdubbelde het risico op ischemische colitis vergeleken met geen gebruik (OR=2,29, 
95%CI 1,02–5,15). Na 12 maanden werd het risico kleiner (OR=1,90, 95%CI 0,44–8,13). Door gebrek 
aan statistische kracht konden alternatieve risicovensters niet verder exploreren.
Naast het gebruik van verschillende datasoorten voor het opsporen en evalueren van signalen, 
hebben we ook onderzocht hoe de huidige methoden om signalen op te sporen bij kinderen 
zouden kunnen worden verbeterd. In Hoofdstuk 4.1 hebben we het effect getest van stratificatie 
op leeftijd of het adjusteren voor leeftijd. We hebben twee algoritmes (PRR en EBGM) toegepast 
op meldingen in kinderen jonger dan 18 jaar oud, omdat te verwachten valt dat leeftijd een groter 
effect sorteert door de relatie met verschillende stadia van orgaanrijping. Beide methoden leverden 
vergelijkbare prestaties (zoals gemeten met een area under the curve (AUC)). De prestatie van beide 
methoden was minder wanneer er voor leeftijd geadjusteerd werd, vergeleken met wanneer niet 
voor leeftijd geadjusteerd werd. Stratificatie voor leeftijd leidde tot het ontdekken van signalen 
in specifieke leeftijdsstrata, die niet ontdekt waren bij de algemene analyse. We concluderen dat 
leeftijd een effect modifier kan zijn en dat er daarom gestratificeerd moet worden op leeftijd.
Het begrijpen welke soorten geneesmiddelen een hoger risico hebben op veiligheidssignalen kan 
de efficiëntie verbeteren en de ratio ruis-op-signaal verminderen. Geneesmiddelen, waarvoor een 
nieuw signaal werd besproken bij de PRAC in de periode tussen september 2012 en december 
2013, hadden een lagere mediane post-marketingleeftijd (12,3 jaar) dan andere geneesmiddelen 
op de Europese markt waarvoor geen signalen waren in dezelfde periode (19,7 jaar). Het zijn 
echter niet alleen de meest recent toegelaten geneesmiddelen waar signalen voor zijn: 58% van 
de geneesmiddelen waarvoor een signaal besproken werd bij PRAC waren al langer dan 10 jaar op 
de markt (leeftijdsrange 0,54–67,9 jaar), dus ook voor gevestigde geneesmiddelen kunnen signalen 
worden gevonden.
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In Hoofdstuk 6.1 hebben we naast hoe lang een geneesmiddel al op de markt verkrijgbaar is, 
ook onderzoek gedaan naar andere voorspellers van de frequentie van veiligheidssignalen. 
Geneesmiddelen behorende tot de ATC klasse “Antineoplastische en immuunmodulerende 
middelen”, geneesmiddelen die gebruikt worden voor behandeling van acute aandoeningen en 
niet-biologische geneesmiddelen hadden een hogere kans op veiligheidsproblemen na toelating 
op de markt. Daar waar de totale duur van blootstelling voor toelating niet geassocieerd was met 
de kans op detectie van veiligheidsproblemen, gold het tegenovergestelde voor de totale duur van 
blootstelling na toelating. Voor geneesmiddelen met meer dan 1.000 patiëntjaren van behandeling 
in de eerste twee jaar na toelating was de kans op veiligheidsproblemen 2,4 keer zo hoog als voor 
geneesmiddelen met minder blootstelling in dezelfde periode. Na een zekere drempel (ongeveer 
10.000 patiëntjaren) bereikte deze verhoogde kans een plateau en nam daarna af.
Om regulatoire instanties te adviseren over welke criteria in beschouwing moeten worden genomen 
bij prioritering van veiligheidssignalen, hebben we onderzoek gedaan naar verschillende triage 
criteria (zz). We hebben 48 verschillende criteria geïdentificeerd, die in 4 groepen kunnen worden 
ingedeeld: noviteit, impact op de volksgezondheid, bewijslast en publieke- en media-aandacht. 
Meer dan de helft van de criteria (63%) had betrekking op de bewijslast, terwijl 19% betrekking 
had op de impact voor de volksgezondheid, 14% betrekking had op publieke- en media-aandacht 
en 4% op noviteit van de associatie tussen het geneesmiddel en de bijwerking. Van deze criteria 
hebben we er 15 getest op de voorspellende waarde (het vermogen om een daadwerkelijk signaal 
te voorspellen), waarbij 11 positieve resultaten opleverden. Hiervan behoorden de meesten tot 
de bewijslastcategorie, zoals meldingen uit meerdere landen, kwaliteit en volledigheid van de 
meldingen. Daarentegen was hoedanigheid van de melder (of de melder wel of niet medisch 
onderlegd was) niet geassocieerd met echte signalen. We hebben 6 besliskaders gevonden in 
de literatuur, waarvan we er 5 getest hebben op validiteit. Ze bleken alle 5 redelijk bruikbaar, en 
tenminste 3 ervan worden reeds gebruikt door verschillende instanties voor prioritering.
Hoofdstuk 7 bevat een algemene discussie over de gevolgen van de uitkomsten van dit proefschrift, 
evenals aanbevelingen voor de huidige regulatoire praktijk en toekomstig onderzoek.
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